var title_f13_32_13824="Open book fracture pubic symphysis diastasis";
var content_f13_32_13824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Open book fracture: Pubic symphysis diastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 376px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF4AdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBYRyAegPrWrb7mbA/D2FZqLiQYXJB71sWwyBjrX3Ej8noq70LcCnoSa0IvlAz0JqnCNoXFXYeeSMelYSO+CJXkaLYVieXc6qQmMqCfvH2FadqmJCx6mqMeT7VoQdAaxnsdEdzUtiMVZ7cnAqpbng4NXY+cVwz3OmIqitXS+EaszGOtaWmZO70rmq/CdOG/iIv1j60iqg2/3iTWxVDWE3W4I7GsKTtNHfio3ps50DknpUigdDyKcVpMflXo3ueNYga0imnLEYb+8PWrsMa7BnqODUSkKeKkiYgtnjmlJtjLCjtU0S/Nziqob8asRt8vSsZJjja5MyjOKCvy4xUW8k9ePSlDEkgiosy7oa6c8cGmkEdeanGOKYQD0xTTJaIihxTGjPpwascc4pQeM0+YXLcqiMg/N0FSLxj0qSUjqKhJ6c073JasybcfpUbnIzSjkUhP8qSBsYxBHB+tQt1/GpGIGfemM2cEVoiGVruTZCcY3t8qj1JoiQRQxxjgIoUfgKRVZ5jM67cLtRSOR6k/Xink+9WhWA8ntipTwi/SoYwN3ck1PIMflQwI+9JwOKU+/NN/SmTYd2pD+tHakzQDQHJU4bBxwfSlX7mGOSO+MZppIB6UoPHeiwDNiqxO3k96Y54zUzAnpUTYBFUhFW4RZFw2cjoRxVWNZVJEjq6diRgj2NXJBycdO9RNwpraL0JZXkPGOh+lVZmA4zmrb+45qrLjng49a2gZyM+6kOWwuQOc+tZd6wkfcFIHcHjNa9xhQ24gZPHHesO/bPyk8jkrXbSPMxbtHVlCTG44OahYc1M33c85qJuua6Ty0QuA3UZqJ+AamIwOajcDmpZrEjHrUUpVSB0z0qXHTFRyGkarchbrUtp981E1TWZ+Y0kVL4S52qvcHAxVnqKq3JwMVbMIbmNc/wCtNFJcsqykHrRXO9z1Y7I6gA78gf4VrWwJRex71Uhibg559PatKBCBjp7VEmKjC25NF93AOABV2EcgjnFVYkJHy1ehUhaxkdkEWEUkg1ftx8o5NU4hyOM1diY9ORj1rGZ0RRegIwAKvxHBHpWdEASA2DyCOKvwnI+nBrjqHREssM9Kvab1NU+q5xxVrTziXr1rkn8LOmhpURo1Xv13W7DFWahuwTA4BAOODXNF2aPUqq8Gjn3UhsGm7MVbkTcPeodv513qR4jRXYc06pGWmlaq5NhVbBp6secVEMU4dc5pNAWByaeOtRpkrTkOW9cVmyiU9MnvTWAwcClBBpD6VIxucUu7J4poA55NGcHiqJBvunioV4NTvgKT0quSDinElkikDn1qMkd6UHHNNYdPeqSJGueajzTyeKizg1aQrDs54PWmNxSL1ye1K/IyO1UOwiH94MfjUzkGoEPzg4wO9SnpQ1qIaxwaaSAeacR+dRsefehCF3DkZppfAppP4mmFcseuKpIGEkny0JJwOaSUDHHNQpjrycVaSsT1Le7jANMLDHvTQoZfmzxz170hwQfWkkBGTjJ7VE2CCPenv0OagkJ7HA7VrFEMZKRk1VlIHXmrEjcHnNVJMg5reCMplW5GSCc4BrMvyisSR83Q9s1qzDcDkdPesq+RSR97ceh9a6qe5wYle62jLlU43YJHrnpUDfMfSrMyGMkFgR161WaulHkvRkZ4FRNg9alPJqF+c0mXEYcAcY5qKQ/nUjAEc9BUD9D7UmbRRE55xVqy71UPTNW7LOPeki6nwlw9KqXJ4z3q325qndHg1b2MKe5zt6/788iiob4n7QeKK4pPU9yEfdR6ukK5GMVPHGS3AyKkjQYyRzmpogN+MVDZUYjokxwOMVaVe/amxgAdOKlRT0HHes2zZIdGMfXNWkTdw3ODmo4UP1Jq1Gh44z71lJmsUWIU6Yzg1bt/9ZIMdx/KoYRkfWrMS7XJHcCuSbN4ourzFx2qWxOJgKjhxt60+3OLhfrXLLZo3hpJM1aZMN0TD2p9I/3D9K5Ueu1dWMg89aaY8j3pwPzGnjkcV13seKlcrMvFRkVZmUe9Q9KtMlqxDjnijv0qTAxTTmruSJk8U+M4qOnA/LSaAnznnvT+vQfWoARxjNSL0qGhpiHnPFJng044zmmscDnmhABb93zVds089OKjY1aRDHq3rRxkU0Ggnt6U7CEfrxUTEZ460+RsVRnn+fC4OD19K0jG4noSyMcckgdaYJfm6iqUsjE5JOB2qFm963VO5DmbEZ3HK4+lSj7uDWTDIVOc1cjueMNWc4NDUrlknmom+lL5iNkg01iPpUpFMjBwx5o3fNTSPU0cFgT0qyR8o4z0qshO88cVJK27gfSq49z161cVoS9yyp557UjsO3SowfmyOcDA54pu7PX+dFguIeB6ioJG64+gqZjxgHionG7sAB0ArSJDKzN2OSTUMjjPTIqxKikAY75qmx2lhW8TKV0QyS7VxgkZ7VRuSXxjOQcZ9eatytj5VI61Um3BPvEt1reJx1djOkT5iehz82fX0qrMoU9cnvirkqkq4H4VUuBx1Oc85GK6EzzJxt0KzdzVdzxxU7HFV3PJ7U2TBDWJHHX6VC544qU+9QO3GKTN4kbjn2q9YD5KodeSK0rNcRjNKIVXaJMcYqld9DV98elUbvoap7GNLc5W+z9obtRU90v740VxOLue9Cfuo9jSM5yBj+tSouGGfxpyDgDnPvUyozsMdMc1k2apDlU5GeBUsYJHHWnIm5RjtU6IFA/Os3I0jEIly309asqM8ng+1Eaj8fepEQd+lYSkbJEsI296toM+lVo15q0vasJmiLEJqRBiZee4qKM/LnFSk4dSOtc7NFoa3ahuhoX7o+lB9q5D2t0Yr5DN9afGeKklTEh9M0xcV1XujxnGzHSDIOKrYG4mrQ7ioXXkjFOLFJdSIg4xTe9PIxxmm4OTmrRmRspB4FIBj6U7ODyaazCqQgBINSlunNVwwJp5PAoaAeW455pCeKZkYyaD0osA5T+RqCRsGpVJ6VHKu5apbiEDZFIz4FIBgHHNQyuTVpXYmEsmQwzzWdJ14qxvIc9MGoZgC3HX61vBWMpO5XZuu489KYZBjjt3p0gBOKZ5fUjvW6sZO4nmHOenpVmOYmqbZBz+VIrkN6Gm4pgpWNBZecZz2qbzcNgHJxkg1lpKQeDVwSAhfbtWcoWLjIm3Et6VIG96qb8k5IyPagPnqeRU8o7kkpzJnPHtTc7uQcj1qMnn3pyvzz9Kqwh7MQQBgD196jZuMjgUjsM8c5qORs8ZNNRJbHBjj5iPwoON31pqgAFsdqTOS1VYBkjAAgVRmO47QOfWrrAAjBOaiaDIJ4960jZGck2ZrD5WO7ODxjtVd1yM+3FXpFCMRxg+lVJcAYXv046VvFnJOJSkA3ZPQA9T2rOuCwOGH4E5rUmG1D6j9ayLrO5gc+praDPPrRsQO2Kgc/nTzkA81C59MCqZnFCE+nWoH+9gA1Jmj5VHXk0jVaCRpjk1oW3CjNUwO9XIfuA00ZVXdD26dqo3OSDV5yNpyPzqjc4wabJpbmBcE+acUU6cZlOKK5nuexHY9pC89OelWIgd3PFIqdB69qkTiuRs7kiaEY6DipweRn1/OokJyBj2qZBg4NYSNYkqdevOKmVSc9qjjwB2z3qdR3NYyZqhUGQM1YUcVEnqKnTpWUmUiVAcU9enuOlJECT7VKI/m5FYtmiVzSjP7tfpT+1Mi+4PpTq5HuexH4UU7hRk1WGM8VemAyc1SdcHIreD0POrxtK4uTUZOScHmlzxTDnNWkYNkcvBBxn6VHKwVfc1Ixx1qrKck5NaxVzNiEkkGkc9ajLAqMGoyx45zWqiTclB+bNSBuKqhucE1Ix96bQkFtK8glWaMqUkKgkcMOxFWO1Qq3OKk/nUtFDx1occGmnsaCeKQiF+Fxmq8nI6ipZTknmqrScda2iiGxjBc8cUwAY5Ixmhm5OD+VV52OSOQK2irmTdiRo8kFcEetOAx2NV4nwDngY61ItwqjaMt6EnNU0xJoa0W8jt34qu6gZBH41Z88YBK/lUEzK3P+RVxuS7dCLPPI6dqsIRgHsOtVGdSMAcZ65pUmxMkRDZYE5HTj1P41TRK3sXM8A0yRhtI7H0pNwCdcn3qvK4P49vSkkU2SpNg45xSvOCxwapSPhSQdvfpVYSnzMnFXyGbnY0/OycEUiyBTnpWW0zAny2ABPIP8xUNxqHkqWkYbsdB0qlAh1ktWbyzqc5Yce9PBUsDuHFcJNqksudrbRntTP7SnXbskbj8c1XsPMw+vR7HfhQe4+tRPweOhrmdO1ppGEcnBPTnrW2tx5gG3kVDpuL1OiFeNRaBKmHxjBzjpxVOVFxj+7V2WTcpA6iqTt8hPf+dVEmaRQu8kMu496yLlSGI759etaty4AwemOtZUoOCeozwTXRA83EJNlRwR1zUDc9xViQkZLf/XqsTzVmCVhr/dxmoUHzDNSzHgCoAcOKTNY7FxcY/nVuIfLkdcVTXOOBVqN9qZPQdatGMkOmB2/eIPtVK5PXJ7VckbHes+5PBoYU1qZUw/eGimyv85ormbPTSdj3RBuHelCjb7U22bkgjNWOmfSuFuzPTWqEQkAVYU8gjpUGce9TJwMHnFZyKiSrzjNW4/aqqeg5q3HyMg1jM1iSAY+tTRjpjr6VCD0OKnjOOcVjItFqIccdatKtVInO7H61dQ+tc0zro2ZKEV49rDIp9InSlNYM9BbEMgyxqtMAMHHFWZSA/PSql22VArWG5yV7WZDnrUTNyRSA49aa5zzXQkcDZFJINuB2qjNNz8veprh+o6VQPD5PNdNOJnJjllO7HWl3dD2pqJ83T6VKwUdTzWjsRqNVsMegFIJQWI7VDOTnOcDPQVETuXKtg+opqN9Rc3Q04XBXoamB4qnaMduZAM+1Wt3A/OspLUtailvXpSh1KmoGk6imq5xkntRyhcinkO4g/hVRnBP0p92SGz2qgHIY4710whoYzlqW8c5zzUM5zwxAwetPgmJwMA+tVb8ESdRjsauK1syG9LjWkKp6g1GHIGcYPWoWY7jzz0psgJzz29K2sZXJfO2vkNxjBHqfWkM+QQ361Xzn86arHAG3J+tOxHMyVpcjI7GpEbIJLVAFyWyOOaaeCOCB9aAuW5JsxgkfN7mq0twpYEHNQyv8pPNU3kCEZxz+NNRJnPUtSSkdDhe1QFywJBIGOlV1uEbliMA9e1MllBXjuOKuxi5J6j55tiZY7TnGKx7qTzpst144FPmkOTvHHI+lU3OGyOK1ijjqSvoIzbTims2e9RuxwACck8fzNBIHNURy6EqHGGBwR0rptKut8a7mw2egrlfxrT0hiu7BGR+NTNXRpSk4y0OsDkNkcAnmo7legOOeRVWNyRnpzU922UBGOg4rC1mehe61Mq82nnHfms24JDHGck9KsX0uHPzc/Ss6SXBI/wAmt4o86q7sWQ4XnkketVCeee9OkfOATjsM1GxwQM1ZEUI/FQpgvUpG7pSxR4bJpFp2ROgO3ircfAHHAqurKB0qdXHXtVGEhsn64qhdfdNXJnOOelZ14/ymhvQ0pR1MuUfOaKrTzHzDziiuRyR6qg7H0BDxIOOKsScfjTQg3DB5qdwQBx09q4pPU7ktCJF64PNTpjH8/eogBt/zxUsI3Lg9amRSJY1wf8Ksx5HHaoI8AAHrVlCR7msZGqQ9enSpk6VEoPfrUq1iykTRH5q0I+mTWcnBrQhPFc9RHRQ3LKfdp3emRcin1zvc9KLuitc8MKoXLfIpAJz68VpTgHFZl5wn41vS6HDiFZsg4yT3NMLcEd6aXwfWo2kBkwOtdSicbZUnYnI6YqLGTgd+9SXGc+9QGXbnHT1roitNDJ7lhisSgE5PtVd3boMGojJu5z1oLZ6Z5q1G24nK5ExJJ3d+2KI4SOhwvWpGx3605GIGKu+mhFtSxbnBAP0+tSM5jcZwQPWq0bEOOeadcNwO1ZON2XfQJZdzZxjnpTTJx159aoSyMrnHTGc5qSO4GzOenStOSyI5h19uZQQKocgHJNT3UxIHf3qgZSWKnqByK2grIym9SwspU+9QTSLIQWHzJnBI6VFuIOc4x3qMg7utaWRk5MlVsYPr60x2ynGTk9zTN4JGTj8Kd8gTgjd/SmidxjfdHfv6UsYOfek3jpnPtT1YZBAwKfQSWo+UFR8uQarybXVQ/I3A4HtU0khYY5zjg1UlfByck0kN+Qy4mVAxPfj2rLkuN7ZNOvJN3B7dqozSgH07YPetkjknIes5Gc4x1P0pskwZDzgY496pyOBzgMD79Kiab5SvY81djncnsSyyfNweBVcyU1mHaoGbninewlG5Kx3TKcZwp7U5mA96rb8mnbgKVynEsK471oaa3zEjqPesUsKvWjgDrxRe+grcrudRasAccAfXrU11Lm23A5B6VjxTkJnPA5z0xVpp0bTiwxjGeuaza1OqMvdsZN5KGck9xwKp7skiieTc5NQliT2rXY5LXdx7gOpB5BoRN5yTxQgJHJp5kSNB/e9KYvJDm2ovP5VWabLY7CmTSFulJFH3bp70r9C1FJXZYDEirUZJGB0NUi+MBemasqeDVJmckLI3XH0rMvGwpq/K3B+lZOoPhDzUzehrQjdmJMxMh5oqCV8P1orzXLU96MND6ex843Dj1qZ8EYOc1UDkHBz17VOScA+vasmhpgFKnODg+lPjAHTrTEYjqSB6VMrd+vtipY0iRVGasLjAwaiTp9egqRTzWTNEiQHauWYfU1MhG0Ec56VBtJZc/dBz9eKdgK6beNx5x0PrWTKLIPPHSr0R+XrVBauQHK1jM2pvUuQ9TUpqvCecVMSa55bno037pFccKMmqF3zGeKuXZ+UVQuG/dt9K1po5MRL3mjPYENkVWmbZMpp/md8nmqt5Ic8dveu+EdThk9B10STzVCQ47HmrZbdH2PFVJj8xPet4K2hlIarcgjrT1bAyarEkAevvTgWx1rVozLSfNnqP60pI254qBW7HpTi4UgZyKixSYrSbF+vpS+ZuUAjio3Zc4z+lR+YN3GOeKrlFcZODu6d+9RjAY+3tT5Zst82MfWqs8yqauKIdkPmcbeCOnFUXc5JPNOM67vu1WklCuT+NaJGMpDyxweRUXmEgkdQahMuDyOOuTT0O5cjBDenOasyvfYjeYZBJwT79aabkHhm9qivPlOMdarqRngjOc00iJSs7F9ZV4Y846c1NHNlcd/rWaoCqTnOT9KUXAKjjj2PShoIytuabzZHHbrVWaQKhJJwOgqnJcdPUe+MVBcT4hJY5PTI7UKISqEdw47ZHHXPeqLyDA4HByPSklmUrnkn1qk79cYB961WhytuRKzjnn3qtI3fmlLDPXFRPIm7ZvG7G7GecUNhGIMx6AmmFj3JoY+hqNifWpbNUiQN8w/pUm7NVlO1hkmpg+BQmEoi5PrVu3JxjpmqQJJ9KtRnGKqJnNaGgG2Jvz/8AXNWI5C9hIo4GeazJGBxkDI5BqzGxNiwX15psiLsU5MFuR3phHPtT9uTUcrgcChguyHM2Bx+NQO5Z/ekZiRxSA7frSbNFGw8krg96je4OP6UjkZJ9aruRipcrFxhfcsRTZkANaMbdKxEP7xeorVjbI4/OnBkVoWHTNge1YupyYRq1ZjkGsDVWO1h0FRWlaJthIc00jBmnbzDzRULg7utFeRzM+rUF0Pq5gd3U8VP820E8mgR88/WpmjG0YFbOR5SRBnBAIFSRuCwHNIYlyM05FXIHUmk2ilcsrz0qdM4HFQJjoKmjAHFYSNESD0HWpFwaZjB9KGYpG77GcgZ2r1b2FZsosLnGaswZxioI8bcmnPOsQJNZNX0RcdNWXosZHSps9axLRo5ZQ0buoPOFc4/LpWpHuVcM5c+pAH8qxnCz1OyjUTRHeYChsDcOAe+KzpXBUjPWruoNiAnnjvXL39+Y8FDmunD03LY5MRNKV2F03lNlScZqpcT7ozt6jkA96hfUA42yDB9apTSHjB4r0oQtucEp9i9BcMYgD1p7sc5zzWZDMQ4HJNWhcKw9ParcbMlSuglbPUfTFNB3DqaC57YpFPJwMUwJNwVcscD3ppkAHQ0hJ5HFRP0PNCQDZZcjJOM+9AlHHpVc5HbH4VFIxDDmrsZORbZwy8Y5HWqVy/f2qxA3y/N2qpeggk8E+lCFJ6XKbS4yOv41GZCWXB6jFRXBIk+pxjNQsAADv5HOa1SOWTLMcoBZc5Hb3q/byIsQwMVhsyn5gfxz0FXbYhFJJ4PQHtQ0OE3sS3Dq/XAz7VnvJsDHqw7mpLw8h8jjjFZszgp8pyCTmqiiKk7FmSY+Xkt1zjB6VXllBj2N9w+hwf0qq85LEk59iKjMo2bT35rSxzuXYsK+xiwJyc8sd2fqajuZztIyPeqzy++D2qJ3JXj6UtEO8pbjJJc96Z5hxTCOajJ7VDZqoolL561C+1XZwi+YRjPc0M3B5qCQk1LZpCJI03FRtMecVEeTUZYjp+dQ5GygiyshLc9amV8n3rNRiH7/AJ1aDGiMgnCxbjbnirSMcc1ShNWQQBkflWsWc00PMmc5q9ZMTbPjPXms0nIrU0oN9mk2/WqT1M2tCtO2wHFUXbc39as3WdxBqizEN70pMqlHQlVs9KQtQvTJGM96a3X1pF21Gs2DnNQO9SydOtVnqJM1gh0Tkyj68VrQt8tYsH+tFasX3eKdNk10Plbg9qwdUbqB1rZm5BrB1Q5DZqa7901wUffRitnPFFNc896K8o+mPrTePxNTlv3fvWeTxyePWrSnMY9TXRKJ5KY/qOTTwfTqarbj0HWnsSQMGpaGmWoz7/Sp42yOKohyMAdqnVuMZrOUS0y8rA8GnDrVNXYDgVYjbIGaycbFJlhTxxWbrU3l2zAdTxWgprD8QkhMe/NOjG80FR2iWdCuQxjXuOK6fOe9edaLOyahEAeCRxXoAPyjmpxcLSTKw07plbVnxZSnuATXnNxcNM+eg/nXomqnNjN/un+VeUzT7SfpXRgV7rOfGS1Re3ZI70srcDB49KzhcM3B/CpGkOOSRXfY4+a5Y8zHPepFl4POTWf5pHJOM9KQXB644zRYnmNWOU59vWp1kGODWMlzxzxz3qzBcryMgmk0XGZo+Zg46mo5Dlc559qrmQlsk80CbIwePalYrmJGzjHU1Cx54JNK0nJxiomkCjiqREmBfBwelQX0pKggUksg4GKr3Dhk5GRTRnJ6FCd+Tu4GarPKxXAIHPrTpztY57c+xqhNKCQNoU+x61tFHFUk9i7HIDuGMnGOe9WopWBGPxrPiAbD5H5dKnd1Qc5JI5NDQ4SdhLy4x8oGe5zWZJJjkdBS3EuWJGcVSnk44p3SIs5MdNMDn3qEzj1qtI+Txmosk96hzN40lYv7wenNKzgKRnFUlbHfpRJNhevWlzD9nqSPJjimeZVbeSetNLnPWoczVUy2zA+lQO1RCTjmmM5P0qXMuMBznHTk1ETjrQzk8mmnJrOUjeMGC/eq3GSQM1TBA781ahf1p02KtGxcjAA9qmBwvHSq0b5HSp1bP/166Ezikh4BxzWxo5AikyTnHFYxOTitOxcxdO4wauOplN2s2Vb4hWb+VZzEk1f1AHzWB9e9UScMP61Mty6eiJUB2ikzg07GEqJjg0hrUbIfWq0nQ1PKcY/Oqsx4OTUSZvBBCf3g9fStaLoKxoDmYVrxHjmnTZNdCTfd5NYGpng1uznCmsDUjgGoxD903wK99GS2c0UjHng0V5h9Ej6mV8qMHNWxkpx+Bqip55Bq3G2FFdkkeNEXPPXmlJIPPQ00HJJzxRnuenrUjRKCcf55qeNsAjsOKrqcEip16cYNRJFomU+/FTLIAfpVPdjIJwTTw+0A1m43KTNKNwRms/Xod8G7FSRTEc8ValUTW5HrWa9ySZT95WOOsP3d9CT2YV6Ehyg78VwssBiu1yOjCu2iP7pPpV4vWzJw+l0MvubaQdtprx+8bbM4xzk17Bcf6th7V4vrJZLqdRnO4/zrXAdUYY52SYiTYOe+fWpBPwVZs5rKWZh1xwT06U8TcZJGPavR5TzPaWL0s4CKO5pUmOMdO1ZjT/JkAgeuaVJz1yAQKfKJVNTREp3EHoPwoWfa3ynpziqBmIAbAI7imRXBX5i21uwo5R+0SOhW53JnoT1qNrjYOvBrOinzHlDkA0zz8Dv69KhRNHU0NT7ScjacCopLvjkj8DWXLe4UkY+lZk9y0jE5wM9KtQM5VrbG99sByN2W4x9Krvdtn5Tz9axUlbIANWfnBBIyPrzTSRi6kmWbiZXDZxVJeeeOKd1yPWliRt2QBkY4PerVkZNuTGO7RngkEVD57E7eeelSsCWqsTtb8aGxxSFYk8VC5yD6VMOvtUMy5bPNSy4lSRcimBCOR0qxsA5bHWmuvFZtHQpFZjg8VDI/FTSEA+lQkA1nI2iRhjjkHFIz9hSsP0FRHr71DdjWK5mO3E00nr7imk/Skz1rLmudCppaik8UmTikY9KbnNTc2jHQenJzVmIjB9arJjmpFOOlXB2Ma0b7FtWGR61YVxVOIgnJqwuOK6Is4Zot2/zv9D3q6jAMKp242r9elSq3NbRdjkmrsffEbQazMjdjPNaEh8yM1nuMNUzLo6KxOT8vWoc88mnKSRionPWk2aRXQbITuOTxVWRs/SpXJHFVnOTWM2dNOI6A/vRzWzF90ViwczitiLgdaui9CMUrMZcH5T0rn9SOQR71u3J+U1z2pE8D3rPEv3TfL176KGM8nH40UpznoKK8657x9PIcdT1q5ESVwOMd6zEYlgBk+vatG3RmAOcCu+R4sRdwzg9MU7nPHrUixqpGTmpcp6jNZuRaRDjBGOtOD4OM8fSpQyHAyBz2oKoR94ZPpSv3KsMLk8npTS/OR+FDxHqDzUX3cgjimkhallZeuelXLC5BIQkDPHNZJbrgce9NDMjgqenNKVNSQKTRf1SA7w6joeRW7bHMC/SsmOX7TAD36GtW34hX6VyVW+VJ9DaG90LKflbmvFfFAIvrgDoHJr2mUnFeL+MkxqtyBzh84FdOA+JnJmHwGH5g2/MT1zj3p/m/JkZFUmbLc/rS7iAa9Q8bUkZ8+uB60u9sjHX39arqSSOc0MSOQeKdxKJP5pQgH8ab5mTktzUDEk55pN2TjPalcfKaVvc7Q2TlfT1qOWYjp396qI+09Tg8YFPYkrwcChDd2EkoI96iZs80Hvmj+dFxJD4wM5P/AOqrSzncDnt0qpngY/WgNyc0XCzuX3fIJyv4Dr61BvP/ANeo/MyMdxxURfBI4p3Js3uSuec5qBySeOlKWOOBUbMAetJsqKJF68/zpXwelQI2Tz6UrNgHNK4+XUa554xUEr/lRK3PFQM2OvSobN4xBuabwOTTGkphbOTngVm2bKLFc8dKrt1qRmPeo2HaspO5vTiMYimZyKexFRk8daxZ3xQjtjrnNRh+Rg0OeOtMQd81m3qdEY6alqM8detSjGOtQxcrwQamArWJx1luSJxjPSrUPJWqyDPpV+zT+I10w1POqOyLB4XApityafLjkVEn3q2ZyrYmV+RnpUFxGVY45HWlDfOMVYmXzEDDtRug+FmfuwSM8etI7ZOKSUYzUAfOVrJux0RjfUbKxyarsfWpH781WmbA461hOR30IXJrY/vDj1rZjOAP0rBsmy5PvW1EcqK0oO6MMdG07DbkgLkVzmqNyATit67b5SBXM6u/zjk1lipWidGWQvMgLgcAZoqp53+TRXne0Pd9kfVImjjOOCxqaK5yh+bFc1b3+44fvWrbcp14+teu42Pm4z5ti8Lhm+XvUgdjiqYl28Diplk4qWjRMnLNjg0KzA/NnHtVffk5p28kkdaQ7lgXDg96ebjuMVTMnHzUcN0zk0WQXLZmUjkUnyngGqjMwGB17GoRNtbAzmiwnI29Pl2S7W6HiukgP7scVxENyC3zYGOldfp8vm2qnNcmJhpc3oy6E8ma8e8ejZrE4Axnr717A/Iryf4iWznUWcLxjOavAv32Y45Xp6HDEjJ5x2ozle9Ry5V+e9Krce1enc8jlQpY5x2FAk9RyaYDnjrQWAOD2pBYfknkU3BU5/SkMgwAO/ejzB60DJCx43d/0pRIcVEGy3Y0Fu9NMTVyYPnnPIqNnAJIqPeeTTC5H9KLjSJt+aBIAx7gVWLkdKaXqbjUS7vYgEdqQkdSR61VWUd6eXwKfMLlsT7qhkwTTN4IphY/xY46Y9KTY1EmVgBzTJn2jGTzUW/mopyT9KTloXGGokhGetRFuuKjJPHWmls9eKxcjpjAczUm7A4phIzSA1m5G8aY7t15pDzSZFLkVLdzVRsRtkmo2WpGI6VGW4NQzphcjbrQqk8UpA9aljAqErmrlyodEmB9KmU4qMfXingEkY7mto6HDV97Vlu2iLsAOlasSBBgVSs41iwzffIx9Kukj159a7IKy1PJqu70EaPPfvTY48EngU92AHFRCXGKrQjUaygHgc1KsnynNVZZMHg1BLOVXAIqeaxapuQtzKM9M1Tc8kjihiWOSc0yueU7s7adOyGu3XNUp361YuGwOOtZc8hDcHiuWpKx6uHp9UX9PbJY+9bcTfL1rn9Kfdu4rcib5Qa6MM/dOHMI2mR3RyK5nVsmb0robp85rkNadjcHmsMZKyOvK4O9yJiueWFFZbMc9TRXmcx7fKfRdrIBjLAk9xW1ZTExjLZOc1xySkH7x57VsWFzmHdzuJwa+nlE+Eo1baM6Fbgjgn8KsRTDsfzrBinV2Oc9OaswyjJwx61k4nXGdzZEmCMCnCX16/Ws8yYxyaFmz7EVNjTmNEucD0PpSo5zg59KqRyAjr2qVGz1NKw0y8h3JhuapXQKMSeQalQnoD7UTYKkdSaSG9UUPPw3Xmu28NT+ZYY5+U4zXAyoySYB59K7Dwe5Ns4PY1liI3gVQfvWOiZiTgZx3OK4zxdEstxgryVrsnORzXI+LMi4Qr6Vz4bSZ0V/hPLNas/Ic7emax9+GI5rvL6AXAIdVIrk7+xaNmIHGeteotTxpLlZnh85PNQSSnPBqZkbHTmqUrfNgipk7FQjdkyynueKeZML1qvCSRz0pWbBPFK+g3HUnEop6zep59qqKwPSnrz2o5gcSx5mQRximFuxqL+E460hOQM9aLiUSUsMZqJm4/rSNwP8KaFzSbLSsODc5qXfuwOtQlSRxSpE2aFcGkTK2R0xSFh60qQtjqKR43GBgVWpGlyFpADULykk+lLKjA81C3FYyk0dNOCYMcnmmkgD6U0nB5NIx461i2dsadkKWNN3elIT700nHSoubKBJux16UjPjpUDPUeTmpcjRU09yVjzTS3vzUbMSc5qNiSTgVLkaqJKZMsBViM4HX0qtFExbJGKtxxjPPNON2RUaSsSIC33elX7eMINzde1VQcDinmRsYBrphaOrPKrOU9FsXGkyeKswv8gJrMiJJqRrj5sL0FbqfU5JUnsi7PJ1OTVJpueDmmzSkjAJxUGamU+xdOlpqSvIexqFie55pSTUbn5gaylI6qVPuOBoyOajDZGaazcVnzWOj2d9CrqUh2jaOnWsd2JfrxWhdtyc9KypWwxxXFWlqerhocsbGxo/JatuNvlxWBohB3VtqeK7MK/dPMzGPvkd0flJ9q4zVpMzmuuu2wh9cVxWrtm4ORXPjJHZlsLK5QY80VG3XrRXn3PXse6jIJq/pxfkDgE1miQZ6Vds5AGPzEY9q+sPzlJp3NBd4k3AjI4rQifkbugrNE4B5wffNWorgHODgdaho6YSS6mohYnHbpzQy7c8moYZlPBPTBFXN4YBexrM6FZjEdgQ2eKuRtkBicVQLZYjHFSwzAYGfbFJoaetjQUhx6U9s9OlV4ZOMAAVMzcehqTRFS8TIyvUV0Hg2Q7JV4PNYbHJIII7D3961/ChC3Eqioqq8GVS+M67sRmuT8YYVoj611Kn1rmfGKjyYzyMGuXD6TOmt8DOSZskg9Kq3UCyDDAGp+Qc55olbJ4PGK9FHnSs0cze6axDOgGPY1z93DsYgjkV3joCc/pWJqlikoYoMHv7VTXMY25NUcuhxTXPXI/OrTW7xvhl4qCRB9azaZopJsiQ4NSq3PFQng0ofHUVCZbjcsA+/Hrmkzk89KhVwakDDFXe5DjYVuTxTc/gaUmmkikwSFDEGn78HmomJxSZ9aV7D5bl2NxxtNPdhjP4VSQ1OWG2rTMnGzILlh2qpITip5yD0qvJmsKj1O3DxIsgGmufamE89c01n4rmbPUURSR60hbnrUW+mueetRc0URXxzg0zOM0hHFRtkcVLZokSqwJA7VMCD0qmgbcKuwoQoJHNEXcU0kTRnBx3p6txxUSjk1IoPetUznkkSqeKkAyaiHP0qVmCLknmtYnLU02Hu+xSF6mqrzBRwaimn3H5elVyx71E6l9jajhuX4jSSTcoNIGJGWXac9M5qpaSZbb+VW2PFOMuZEzpqMrCk45qF3HvT5DhTxzVd2Oc0pMunDqSbuOfSopmwDTVcH2NMmb34rNvQ3jCzKdyxPWsy4bkYq/cNyfSsq4b9K5KrO+krI29COV59a3e3Nc9oR2r9a3w2QMV2Yd+4eXjoXmVb9sRn0xXE6o4+0tmuy1Fv3ZrhdQb/SWrmxbO3ARtErMRnvRUZPNFcJ6dj3MdOtW7Mc4yBVRQRVm0yG4r65H5vPYsu/zHBBNW4pQEUd/4hVRhsYHjPvzThIRgdCO/rVNXJjLlZpxyMWOGHHp3rQin+Q9z0rDty2C3HUcdjVyKYMuV69KzaOmE+pqM/vzTUlBYcDHr6VUWQEZHP86RpSDgA4A4zU2NebXQ2YXwc5zzxVgNk5zxWVaTfIA3P49KsPOVbAGB61DRqpaFvPzCtTw44W/YYxuFYC3BBGQcVq6DKP7RHuKia91mlOXvI7gGsTxREZrHgAkc1rhh/wDrqjqxP2YkDpzXFT0kjsnrFo8/aN1kIx3pyx54I59K1LyAD50Hyn0rPZf3qnn5e2etegnc4HGxBOiovPGe9ZN0oJO0nkccVq3eS20YA61mTqfMIQjZjqDzVxMal3oUTbq4IYZOcZArNvNN6tH05/GttQ2SGXge/WoZZMEAkH3/AM9Kvc537qucpLaSITlcj1quYmHBzXTyuj5+Xqeo7VUkjQ544rN0kXHENGEI2PbtRhhxitd1jA6VCxTPQVPs7Gvt3LoUAGxwKcIjirLsoHQComkFLlQKTexEVx1pCPeiWTnj9aiaTIqXJI1jCUlckXjNSKcr1qvv5pRIRUqaKdKXYdKOOtQuvH+FOZvWoHlArOckzooU5IY6DdnNQSLkcdKWSXnvUZkznjmudtHpRTQm3PSneTxyaj3kdOKlEuetSrFu/QPK9aDb804NxT949adkTeQkduKsrENuKiif5sHpVhT8vJ4rSKRz1ZSG+Vx75p2zjpS55pc5IGauyMOefUaowM1BdEsuM1Yb7vtVadvmGPpUy2NKWsrkATA70jJTwScDrSkn2rLQ67sjtlKzqcHrWiw5qnGCZFPoauGtKa0ZhXl7yIJGGPXFVHbA461PMhJPOKqShlPtUSbNqcVYN/BqKZv0oLEdDUErcdaxlI6Ix1ILmUAEnmsqV+Se9WbyTsDxWe7fMa5ZO7OuKsjodGUPEOT+FbccCqMgt+dYehH90DXQhvlrtw9nE8/FNqVkZupn92a4e9bM7/Wuy1ZvkOPSuJuSTM31rlxT1O3Bx90hz7UUw8njIorjO6x9A7BnpVqyWMSDIPtiqZftin20pEgPYc19mfmSvuX7hApJHfPBqqpGe49KVpMt/gKa75UYPPegTaexOJjx/SpY5du4lRwKpK5wRSlueRnNGgJtGlBcBWB5AI5HvSvIpy471mbtgBBOakin+VsnGfzpWNPaPY1bdzv4PTqPSr7S84Y1jwy5KEHn0J6Vc8w5GTWbR0RloWBPngYrU8Pyf8TRSCe/WsDfxkH1x71e0OZo7+3GRyeTUyWjNacveR6gjDjmqmpPi2Ynkd6cknyg1S1iYixmPOADXDGPvHoyfumILuN90YP0rJvJFWQj0PIqqsjPJHJDIE+bJ3DOR3HtT9UGTuUdRXYo2djglO8blK8vFEqjPbiqkl4m9QMY9c1nXzFZjz2qnJKQM5zW1kjk55NnRQzwy5Xdgn360y8syfmXkAfw1z0dyQfyq/BqDIRtbA9D0pegN3VpIbNFIuQRj8arMG5zWst9HIPmAJ7n1qrIsRU7T83YHtTV2ZuyMyRcryDVeRDnjNaEiYFVpDtODyKlo0jLsUjknvTSpJqaQgH/ABqPeDz3rJo3TIZ0AORVUjir0uHSqTnArGqranbhm2rDGJB+tCk1G8gIpokwa5+bU9BQ0J2JK1XkzmpPMyDTGORQ3ccI8pXYEtxSBSRjFSbsHpSk8c9azsbXIWQ9KEBzipd3HvTd4DUrDuxQpJpdpyaerAinZqrEXY1Qc4q2gyv4VXyMCrMR+QVcNzCs/duKRTlHFL39qOPetbHI5OwxycVXlTLZqw5FRuR6VD1OiF47EG09qMHvTiAylW6EfSgnHSosb3HxLhh9asNUURBYVIxzWkdjnqXc1chcYyetVJQCKtyYxx2qnIck1nI6KRVkGOgqjcPsViOtaLdKy9RX5DiuWptc7qW5lTS5aqzP7U+Xg9KgJ/OuRs6kjqNBP7pa393yCuf0MAwqR+lbpPyivQoP3TzsQryMnVW+Vue1cXcE+Yx966/V2+RjntXGzEFm+tcmIfvHfhV7pEWGeooprEk8fzorkO/lPfzgj1zSwn5zUIZlUeZjf3x0zUkDZJPQV9inc/MZK1ywTyOeaHxt6896hL/MSeaJGyp5xVXI5RwY/XvSh88d6rKxzzUqkYGe3apTLcepM7c8npTN2DxSNzx39aglfYvUCm2KMS/FOFbJOQOMVeguUIIxjP6VzL3WG4qeK7AIJPHtU8yZrySjqjp3Abbtbtmn2DkanBzxu4qvYzxXNuFZxkdB3qzBsS5iaPOQ30pPYqOruemwNmNfSqWrbnsZl4+6e9T277oUPYgVFec28i9cqa5ErM9Nu6sedWs3zFSehPIPFXmk8yMgY29ue1Y/yxXTg8fMeP8A61XbeVUxjG3sPQV2NHlwndWMfU49kuQxP1rNnHFbuuAeWJI+VxjjtXO3DlhnNDZMVrYYrbTSyMcdarl80pfI5rPmNeUetw69D0qZLon+Lms8tk0mcdOtRz2NPZXNQXLdCePeopJs8mqqS5GG60hOT2xVc9yPZWepJId3eq7EgmneYQT25xTGO41nKRvCDF3H8KqXGR+NWB6dKjmGVOaxk20ddJKE0ZsrkGomkOetNuGw5A7VAzGuKUrHsQjdFpJTkVPu+U4rMSTmr/WPjvThK4pwsJu5oLEjFQE4J96M4z6UcwuUeXIGKN+SKjJ5oFK5XKWI3wOTUqydRVLdUiyc57VSkS4lkNzVu2cFKzS/PvT4p9hx2qlOzM50+ZWNXdSse4qrFKG5zU27itlK5ySpWdhrnk+tNJ4oJIPNNJ9als2jERuaYdwz3pwPpThg1O5ew61yTyKlc4NIhCgn1qFpMk1d7Iya55XCQ8HmqbtzUsj9aquwJzWUmdMIgx49azb05PBq3K+BWbcPnNc1WXQ66UepmXS4Oc1UJzmrl0cg+lUGPJArllodMdTqtDOIVFbRb5fSsHRj+5XtWw7fLmu6i/dOGsveMnV2/dsfauRlPLdOtdLq8nyEZ/CuYlPJxXHXep34ZaETZJopG6+lFc3MjuUT30gu/wAvPNWI12J0zTIkKgFjU8bflX2iXU/LJvoREfnSkHYc9BVrYG5GBjtTVgJYcjH8qbRKkUFUlskVMq/LT9mDjoaRjsQkmpSLbvsQXU4t07FjWRJM0hyxpbqUyyEscgdKiPrXNUqXdkejQw9o3e4uTUyHgVBk+lPUkVMZF1afKtDVsZtoGDzW/aXjNPHn15xXK2r4H+NalvKcgqefaumLujz5rld0ew2bg2sZz1AonOY2+lZ+kytJpcQV9rbOGxnHvVqR8xnqeOtc1tT076HmV+SLubGRlzUMcxHQn86dqjYv5wP75/nVNXNdlzxuXqaazCW3kiYZyODXOXS7CV7itaJ2AzWfqi8lu9TPY0pXUrMzd2R9KUnI5qPsPWg9MVyc56Xsn0F9eTSfSkY8U0tWbkbxhoOBx05pwb0qFm5/ChW60lKxTpKSJSeuaTPvURNKr460ua5XsrLQkz/OmP8AdNPOAKp3E21eOtEpWQ6cHJmZfHEpFUnk5x1qa/fdyDVLd69a86pL3j2qUbRRPGw3CtGOQbQDWSpAHWrUT5HWiErBUjdFhz83Wmlj60hPfiomfFW2ZxiPzyaC/aoSeTSbgDUcxookwf1pyvzg1VL8UBueelLmHyXLm+gNk1WD+lLv9etVzkuBaRyp64qzHdMMbuRWeHHal3+9Up2IlTubCSrIODzQxxzWQkpQ5U4q5HdbhhutaRqJ7mUqLjsWVbIFOB+bFQh/yoZ8DOau5HKTyPgcVWaXimPKxPXioGfBqXMuNMld8g1Wdz0/lQ0nGBmqs0wUGsZzN4QEupscA1nzycUSzbuSc1Vlkzn3rnlK+p0JW0I5nHpxVNm+apJX/HNVy/zD3rKTN6cDqdII8sc8Vqs+UrE0lsRitSR/kyelddOXunHUjeRjay3B965xz8xz61tas+SQelYR659a46r1O/DR0AnnoTRSHnqaK57nbZn0EZMNTw9Uy+WzUqt09a+3uflTjYtrLxz3qcOQPxrPZ9ox2qRZe/WmmZuFyeVjuDdzWfqMxSPaDnNXSwZexrF1GT97g+lRUlyxubYanzzSZWJxSA/rTCw6UgOa4LnuqFlYlGRTwcenNR9ifSnKeOapOzMakLqw9Gwfar1rL83U4rNz0qaGTDfj1rSE9Tmq0fduj17w1Nv0mEn0xmtF5Mg9+OK5rwfPu0sDoFPrW4z8cEmra1FGXuo8+10bdUuBj+KqC8/WrviJj/akpPc1mCQ9D+db3OG1y0uQKiuk3Ie+aRJMg/zpwcMMUXuKzTuY0ibSVpjcdKv3sQ6j9KznbHWuOpHlZ6lCftIg/XNRFsUpbOaiZs+1YNnfCA4sc/1poJwcUzJPank4FTc1sG8g4pN/NRs4x2zUTOc85qWylEuNLxxWddygAmiabAPNY97cFu+BWdSpobUqOo2eXcxPP0qPOeartIPWk8wk+1cTep3W6FoOM1MkmOlUA/rzUgkx7UJhY01fOOaY7Y96qJLkU95BtHPWq5ieU34fD13deD7rxBbBpLW0uhb3Khf9WGUFG+hOVPodvXPGEW96+h/2UYbbV9C8ZaVfxefaS+QssT/dZXWQH8fl/lXjfxT8H3XgTxdc6VcFntT+9tJz/wAtYieD9R0PuPTFZqfvNM1dO0VJHNFu5NMMu01UeU8gnio3lp3IsXGuPenLN3rNMuDSLcY4HSlzDsbAlHY8Uok96y1uh0PWni5460+YLGr5nHFIJCCMVnRz+4p4nGeDT5ibGvDdcANVkyhl4xWD9oGDTTeFRwcVoqrW5DpJ7G00vPWopJRjmsc3p7nNRyXpIwKl1ClTNKW5VQTms24uC2ee9Upbgnr1qBpuetZOZrGmyy0vNRPJkVWMoI4zTGckGsnM2jSHySHP1qJW5FMPWgHkelQ3c6VFJHTaSflFakrkKayNLb5fWr87jYa64vQ82S1MTVH5IrI9q0NSbIPrWf371y1Xqehhl7oUUUVidVj3UNt+tIrndRsz9acIwTX2up+W6Dt5P1oyTQsdTGMHoaqzIbSHRt8vPasTVGxOTWuwC4GayNaUF1cZwRzWVf4GdOBt7ZFDzCTUiPj6VVbr15pVc1597HvuNy8rbh9aerc1UEgAqaNsjpxWikc86eg53x0pUkwaglfmkRzSctSlT93U9G8C3P8AokkZPRuua6jzfQ/WvP8AwXMQ0oGcYBrrhLhcE8d67Ye9FM8ap7k3E5PxS2NTc5rI8zIrS8VNm+3eo61hk05ysyadPmjcuLJ8tHmHnmqgbbSbuetR7RF+xbZcMu4YJBFZ86EEntTw1Lv3DmolJSVma0oSpSuikTUfUmrbxrk445qB1wea5pI9SE00MPT+lMkcAUrsAKgkYE/4VDdjWKuIz5JxTHbAphPcVSvZiideTWMpWN4QuR3t0C21azJpc96WQkk+uarSdetckpN6nXGNlZC7vXpSCTmoTkUA4FRc0sWUbINKZe3FVd3ejdxyaLi5S0kvYmpfOG3Gazt+GA704PjvRzA4n0r+xxdZ1nxPb5b54IHwOnys459/m/nXsHxv+H8fj7whJBAqjWLPM1jIcDLY5jJ9GAx9Qp7V8r/Ar4iWHw71zVb/AFK3u7qO5s/Jjit8cyb1I3ZIwMA88/SvbvEXxX1rxJ8Db7xd4OxpV/Y3vk3cR2zskWQOCy4zh4znHHzfWsZX5ro6qbThys+SrlJbe4khuI3imjYo6OMMrA4II7EGoCxPvUmp6ldapfz3uoTvcXdw5kllc5Z2PUmqZk7VfMYqBIWxTGPHFRljjikL/l71LkaKBKGzinq5A61W3Y796eHHrRzA4FjzCKXzG9eag3e9BYc80+YnkJfNaoy5IySTTGk4IzTNwIpORSgTCQ5IJppfAqLPNIzZ6Gp5i1Acxz1NRlsUN7cA9KYc5HpUtmsYik5IzSGkPaj8ak0sFFHPajv06Uh20N3T3wBzVuaTKcGs2ybAGatTN8hFdieh5Ul7xl375OKqVLdHL1GO9ctR6npUFaIlFH5UVBue65YY4zTxkHOaYzjPFMMoAOTX2t0fllmydTzUqZB5qoJRxzUvngd6aZLix8/XjmqF6BJEQetSSTgggH8Kqs5bknis5yRvRpyTTRntGN2DSMoA4qxcDPIxmqbuwODXBJWPdhJyVx6gEZx0qSM+3vVNpWGRTo5iDU8yNHFltwD1qMYB96ilnIqMXHzZockKMHY6zwpJsnfB6iusMoYH6VwvhqfNyfpXUmX5T05r08NaVM+bzC8K78zG8Rv++jZjkVlAgjI6dqueJ5MJG361gRXuzvxXPiJqNTU78DRc6CaNLPamng1Atyjjg801plyRWLmjrjRdywTxUZcg9agaYevFRtOPXFS5msaTLhfjn1qF8Y4NV2uBniojccdahzRcaTWxNIOOtV5FAyc00zAgkmopLhQuWrNyRvGDGyNsHJrIu5d7nnii9vATtU8VnySjPWuSczshAlduetQMSe9RNLzxUbSDPWsXI2jBjyeevFG4kDmq5lG40nmc9ajmNfZss7uKYW5qHzR60wycnFTzFRpssM2KYZPaog/1pjMaXMUqZaL8V7n+ytqVvfar4j8Fam2bHX7B1UHn51Ugge+xmP8AwAV4Gr8Yrd8C+IJfC3jPRtbh3ZsrlJWUH7yZw6/ipI/GhvQpQsylrOn3Gj6xfaZerturOd7eUejIxU/qKpbuPSvZP2rvD8em/EhNassNYa7bJdxun3S4AVseuQFb/gdeK5596nmK5B+c9gDRn/8AXTDQOnelcrlJAwzn1o3Y65qOgUXDlJSf1oz7mmZ5oySMcUcwuQcT+Q7UhY5pvejJzRcfKBPPFGfakNJSKSHU36UtBpFJB2pKXAoxSLsGOKQ0vOaDxQDL1o2AtTzP8pqnbMR26VNM3BrpT0PNnH3ilKcvzSdjSZySaWueW56NNWQYoo/GikXY9lZ+lBJphbGMU0tivrHM/O40SVWwc80rPmogaVm9TSUmgdJNisQD61HIwHc0xn5qJ2GDg+9Q5HVCkP3A8GoJU3jigNk0obnacCsm77nSly7FFxtyD1pgbnFSXjAMfeqPmfPXPOVmdUFzIsSyVGH561DK/HFRh/Ss5T1Now0Ol8OS4vAK68uOea4LQJMXiZPNdl5nFergZ3gz5rN6dqyfkZfihs2q49a5Ey89a6jxK2bBj6GuLL/lXJj5WqHqZRH9x8y8twVPBqRboMcZwayxNiopZsHg81xKo0ek6aZtmb3qN5vSsX7W4PDUG+IwCKHVuJUkjVMpBqFp/eqBvQenFVpbrrg1DmaKBpSXYXvVC4vS2RmqLyluc8VEzkd81m6hrGkSyS5yc1Ez5qF5MnFRl+MdqyczojSJTJzxUbvmmk5puazcrm0YWFzk47UmfWjuKO9Tc0URTSZopaVxqIg60UDrS0DsIODS59+KKMUXDlOq8V+Pda8U+HdC0bVmt3s9Fh8m1KRYfbgL8zEknhVHYcCuV70Y4o6Dii4cocig9KKMcUXHygfzo6mgjvRSHYMAUUuMdqMUBYTmij0o7UBYKKWjHpQOwnalxS9qOlA7CUD3pRRSHYQ0Gig0xEkJx/8AWp0rDFQocGlc5PNaJ6HI4+9caPelpF6UtZnVHYUY70UhPoKKQz1pXzxSsw7UUV9NdnxfKriB+KQyYJoopXdgUVcgMmTTWk/OiioubKKIzJimed19aKKhstJFS9lGPeqO/npRRXNUep1017osjgrzUQcA80UVDLRpaNIPt0X1xXZ+ZwPpRRXpYBvlZ4WbxXNEzNebdYSfSuEkkIbrRRWOP+NHVlWlJ+pCZOeDTJJM96KK4Gz1UiBn96jeWiis2zWMURtJjvTWkycCiiobaNVFDGfjg9ajZsnvRRUtmsYoYenNJnpRRWdzZIO9FFFI0sLR3oopDCloooDoGPyooooADQBRRSHYAKUCiigaQUAUUUAhMc0tFFAB2ooooATFGPSiigLC0dKKKACloooGFJ2oooBgaQ9KKKZLEHWkP60UUzK2o5aWiipNlsFFFFAz/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anterior-posterior (AP) x-ray of the pelvis reveals significant diastasis at the symphysis pubis of this trauma patient. Such fractures can cause significant hemorrhage. Emergent treatment consists of closing the fracture and stabilizing the pelvis by applying a pelvic binder or tying a sheet tightly around the lower pelvis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13824=[""].join("\n");
var outline_f13_32_13824=null;
var title_f13_32_13825="Subacute cutaneous lupus I";
var content_f13_32_13825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with a photosensitive eruption on the forearms and back of hands. The lesions are hyperkeratotic, making one suspect psoriasis. The history of photosensitivity suggests SLE, which is confirmed by biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13825=[""].join("\n");
var outline_f13_32_13825=null;
var title_f13_32_13826="Air in fistula tract EUS";
var content_f13_32_13826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Air in fistula tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing air in a fistula tract (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13826=[""].join("\n");
var outline_f13_32_13826=null;
var title_f13_32_13827="Division of liver tissue";
var content_f13_32_13827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Division of liver tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The liver is gently 'finger fractured' to fully expose any vessels or biliary radicals asociated with liver injury. These are then clipped or tied.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13827=[""].join("\n");
var outline_f13_32_13827=null;
var title_f13_32_13828="Desonide: Drug information";
var content_f13_32_13828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desonide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/612?source=see_link\">",
"    see \"Desonide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Desonate&reg;;",
"     </li>",
"     <li>",
"      DesOwen&reg;;",
"     </li>",
"     <li>",
"      LoKara&trade;;",
"     </li>",
"     <li>",
"      Verdeso&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desocort&reg;;",
"     </li>",
"     <li>",
"      PMS-Desonide;",
"     </li>",
"     <li>",
"      Tridesilon;",
"     </li>",
"     <li>",
"      Verdeso&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Corticosteroid responsive dermatoses:",
"     </b>",
"     Topical: Cream, ointment, lotion: Apply 2-3 times/day sparingly. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Topical: Foam, gel: Apply 2 times/day sparingly. Therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F157922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Children &ge;3 months: Foam, gel: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Verdeso&reg;: 0.05% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.05% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DesOwen&reg;: 0.05% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [aqueous]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desonate&reg;: 0.05% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 0.05% (59 mL, 60 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DesOwen&reg;: 0.05% (60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoKara&trade;: 0.05% (59 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.05% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DesOwen&reg;: 0.05% (60 g [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes foam, gel",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use on open wounds; apply sparingly using smallest amount needed to adequately cover the affected area. Use of occlusive dressings is not recommended. Avoid contact with eyes or other mucous membranes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Foam, lotion: Shake well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatosis (low-to-medium potency corticosteroid); mild-to-moderate atopic dermatitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Dry skin, erythema (transient, intense), peeling of skin, pruritus, rash, scaly skin, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: HPA axis suppression, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Application site: Atrophy, burning, dermatitis, irritation, itching, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Asthma, cough, pharyngitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reported with other topical corticosteroids, may occur more frequently with occlusive dressings: Acneiform eruptions, allergic contact dermatitis, Cushing&rsquo;s syndrome (children), folliculitis, growth retardation (children), hypopigmentation, intracranial hypertension (children), miliaria, perioral dermatitis, secondary infection, skin atrophy, striae, weight gain delayed (children)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desonide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Chronic use of corticosteroids in children may interfere with growth and development.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3401417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in rats or rabbits following topical administration of the cream in doses similar to the maximum human dose, based on body surface area. Teratogenic events have been reported following systemic use of corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3401419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3401420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. The extent of topical absorption is variable. Use with caution while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F157900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Desonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $15.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (DesOwen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $367.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Verdeso External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (50 g): $210.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Desonate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $449.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (DesOwen Lot w/Cetaphil Cream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (1): $210.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Desonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (59 mL): $153.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (DesOwen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (59 mL): $315.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (LoKara External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (59 mL): $98.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Desonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $15.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (DesOwen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $274.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10111945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HPA axis suppression (ACTH stimulation test, AM plasma cortisol test, urinary free cortisol test); signs of bacterial or fungal infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F157901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apolar (FI, ID, NO, SE);",
"     </li>",
"     <li>",
"      Dermanide (ID);",
"     </li>",
"     <li>",
"      Dermonide (KP);",
"     </li>",
"     <li>",
"      Dermosupril (PE);",
"     </li>",
"     <li>",
"      Desoclin (KP);",
"     </li>",
"     <li>",
"      Desolex (ID);",
"     </li>",
"     <li>",
"      Desonia (KP);",
"     </li>",
"     <li>",
"      Desowen (AR, AU, BR, CN, CR, DO, GT, HK, HN, IN, MX, NI, PH, PY, SG, UY, VE);",
"     </li>",
"     <li>",
"      Deswon Lotion (KP);",
"     </li>",
"     <li>",
"      Dong Koo Dermo Lotion (KP);",
"     </li>",
"     <li>",
"      Ezenide (MY);",
"     </li>",
"     <li>",
"      Locapred (CH);",
"     </li>",
"     <li>",
"      Locatop (CH, CZ, PL);",
"     </li>",
"     <li>",
"      Reticus (IT);",
"     </li>",
"     <li>",
"      Sine-Fluor (ES);",
"     </li>",
"     <li>",
"      Sterax (BE, CH, DE, LU);",
"     </li>",
"     <li>",
"      Topifug (DE);",
"     </li>",
"     <li>",
"      Tridesilon (CO, CR, DE, DO, EC, GB, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Tridesonit (FR);",
"     </li>",
"     <li>",
"      Zotinar (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Dependent on formulation, amount applied and nature of skin at application site; may be increased with inflammation or occlusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13828/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9331 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13828=[""].join("\n");
var outline_f13_32_13828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157907\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157908\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157934\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157910\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157922\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157911\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157893\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157880\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157896\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157894\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157933\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157899\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157884\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299139\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157889\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157890\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401417\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401419\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401420\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157900\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10111945\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157901\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157883\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157898\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9331|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/612?source=related_link\">",
"      Desonide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13829="Ibutilide: Drug information";
var content_f13_32_13829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ibutilide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/19/26931?source=see_link\">",
"    see \"Ibutilide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     <b>",
"      Atrial fibrillation/flutter:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;60 kg: 0.01 mg/kg over 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;60 kg: 1 mg over 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue infusion if arrhythmia terminates, if sustained or nonsustained ventricular tachycardia occurs, or if marked prolongation of QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     occurs. If the arrhythmia does not terminate within 10 minutes after the end of the initial infusion, a second infusion of equal strength may be infused over a 10-minute period.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Dose selection should be cautious, usually starting at the lower end of the dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as fumarate: 0.1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corvert&reg;: 0.1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse undiluted or diluted over 10 minutes. Observe patient with continuous ECG monitoring for at least 4 hours (&gt;4 hours in patients with abnormal hepatic function) following infusion or until QT",
"     <sub>",
"      c",
"     </sub>",
"     has returned to baseline. Skilled personnel and proper equipment should be available during administration of ibutilide and subsequent monitoring of the patient.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute termination of atrial fibrillation or flutter of recent onset; the effectiveness of ibutilide has not been determined in patients with arrhythmias &gt;90 days in duration",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ventricular extrasystoles (5.1%), nonsustained monomorphic ventricular tachycardia (4.9%), nonsustained polymorphic ventricular tachycardia (2.7%), tachycardia/supraventricular tachycardia (2.7%), hypotension (2%), bundle branch block (1.9%), sustained polymorphic ventricular tachycardia (eg, torsade de pointes) (1.7%, often requiring cardioversion), AV block (1.5%), bradycardia (1.2%), QT segment prolongation, hypertension (1.2%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): CHF, erythematous bullous lesions, idioventricular rhythm, nodal arrhythmia, renal failure, supraventricular extrasystoles, sustained monomorphic ventricular tachycardia, syncope (0.3%, not &gt; placebo)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ibutilide or any component of the formulation; QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;440 msec",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Monitor for heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects:",
"     <b>",
"      [U.S. Boxed Warning]: Potentially fatal arrhythmias (eg, polymorphic ventricular tachycardia) can occur with ibutilide, usually in association with torsade de pointes (QT prolongation).",
"     </b>",
"     Studies indicate a 1.7% incidence of arrhythmias in treated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Appropriate use: The drug should be given in a setting of continuous ECG monitoring and by personnel trained in treating arrhythmias particularly polymorphic ventricular tachycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic atrial fibrillation:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with chronic atrial fibrillation may not be the best candidates for ibutilide since they often revert after conversion and the risks of treatment may not be justified when compared to alternative management.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Dosing adjustments are not required in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosing adjustments are not required in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with any drug that can prolong QT interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and embryocidal in rats; avoid use in pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Corvert Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/10 mL (10 mL): $542.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ibutilide Fumarate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/10 mL (10 mL): $336.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Electrolytes; observe patient with continuous ECG monitoring for at least 4 hours following infusion or until QT",
"     <sub>",
"      c",
"     </sub>",
"     has returned to baseline; skilled personnel and proper equipment should be available during administration of ibutilide and subsequent monitoring of the patient",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corvert (AT, CH, FI, FR, GR, IT, NL, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism of action is unknown; prolongs the action potential in cardiac tissue",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~90 minutes after start of infusion (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of conversions to sinus rhythm occur during infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 11 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-12 hours (average: 6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (82%; 7% as unchanged drug and metabolites); feces (19%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Caron MF, Kluger J, Tsikouris JP, et al, &ldquo;Effects of Intravenous Magnesium Sulfate on the QT Interval in Patients Receiving Ibutilide,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(3):296-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/12627926/pubmed\" id=\"12627926\" target=\"_blank\">",
"        12627926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleman CI, Kalus JS, Caron MF, et al, &ldquo;Model of Effect of Magnesium Prophylaxis on Frequency of Torsades de Pointes in Ibutilide-Treated Patients,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(7):685-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/15119574/pubmed\" id=\"15119574\" target=\"_blank\">",
"        15119574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalus JS, Spencer AP, Tsikouris JP, et al, &ldquo;Impact of Prophylactic I.V. Magnesium on the Efficacy of Ibutilide for Conversion of Atrial Fibrillation or Flutter,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2003, 60(22):2308-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/14652979/pubmed\" id=\"14652979\" target=\"_blank\">",
"        14652979",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13829/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8548 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-ECAAE0F0B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13829=[""].join("\n");
var outline_f13_32_13829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708915\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181555\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181580\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181557\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181558\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897590\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897591\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181537\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181522\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181540\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181538\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174546\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181578\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181543\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181526\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299505\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181531\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181533\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181544\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181562\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323190\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181535\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539879\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181525\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181542\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/19/26931?source=related_link\">",
"      Ibutilide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13830="Levofloxacin (systemic): Patient drug information";
var content_f13_32_13830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levofloxacin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=see_link\">",
"     see \"Levofloxacin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=see_link\">",
"     see \"Levofloxacin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8398376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levaquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8398377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      APO-Levofloxacin;",
"     </li>",
"     <li>",
"      AVA-Levofloxacin;",
"     </li>",
"     <li>",
"      CO Levofloxacin;",
"     </li>",
"     <li>",
"      Levaquin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Levofloxacin;",
"     </li>",
"     <li>",
"      Novo-Levofloxacin;",
"     </li>",
"     <li>",
"      PMS-Levofloxacin;",
"     </li>",
"     <li>",
"      Sandoz-Levofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of tendons getting irritated and tearing. The chance is greater in people over the age of 60; heart, kidney, or lung transplant patients; or people taking steroid drugs. Call your doctor right away if you have pain in the back of the ankle or joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you have myasthenia gravis. Very bad effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had tendons get irritated or torn when taking this drug or an alike drug in the past.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care in children younger than 18 years of age. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, antacids, didanosine, multivitamins, minerals, diet aids, or sucralfate within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tendons may rarely get irritated and tear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in back of the ankle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablets with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid (solution) on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12239 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13830=[""].join("\n");
var outline_f13_32_13830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398376\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398377\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027750\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027752\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027751\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027756\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027757\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027759\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027754\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027755\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027760\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027761\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=related_link\">",
"      Levofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/63/24564?source=related_link\">",
"      Levofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5299?source=related_link\">",
"      Levofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=related_link\">",
"      Levofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23768?source=related_link\">",
"      Levofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13831="Nutrition support in critically ill patients: An overview";
var content_f13_32_13831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutrition support in critically ill patients: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13831/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13831/contributors\">",
"     David Seres, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13831/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13831/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13831/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13831/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/32/13831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutrition support refers to enteral or parenteral provision of calories, protein, electrolytes, vitamins, minerals, trace elements, and fluids. The fundamentals of nutrition support for critically ill patients have been the subject of clinical practice guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/1\">",
"     1",
"    </a>",
"    ] and will be reviewed here, including the goals, outcomes, indications, contraindications, and daily nutritional requirements. Access, formulations, prescribing, monitoring, and complications of enteral and parenteral nutrition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of nutrition support therapy is to supply the substrate necessary to meet the metabolic needs of patients in whom adequate nourishment cannot be provided by mouth. These needs vary with the phase of critical illness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute critical illness is characterized by catabolism exceeding anabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. Carbohydrates are the preferred energy source during this period because fat mobilization is impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/5\">",
"       5",
"      </a>",
"      ]. Nutrition support supplies the nutrients necessary to meet the demands of the catabolic state. The hope is that this will mitigate the breakdown of muscle proteins into amino acids that serve as the substrate for gluconeogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recovery from critical illness is characterized by anabolism exceeding catabolism. Nutrition support provides substrate for the anabolic state, during which the body corrects hypoproteinemia, repairs muscle loss, and replenishes other nutritional stores [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another goal of nutrition support is to alter the course and outcome of the critical illness. The effects of nutrition support on clinical outcomes are discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral and parenteral nutrition appear to confer different clinical outcomes in critically ill patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2782159\">",
"    <span class=\"h2\">",
"     Adequately nourished patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the evidence related to nutrition support is from patients who are adequately nourished when they enter the study, since clinical trials have typically excluded malnourished patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935222\">",
"    <span class=\"h3\">",
"     Enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition may decrease the incidence of infection in critically ill patients if provided early in the course of critical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. This effect has been demonstrated in clinical trials that compared patients who received early enteral nutrition to patients who received either delayed enteral nutrition or intravenous fluids only. Early and delayed have been variably defined in clinical trials but, roughly speaking, early enteral nutrition is initiated within 48 hours and delayed enteral nutrition is initiated later.",
"   </p>",
"   <p>",
"    An initial meta-analysis of three randomized trials (133 patients) found a non-statistically significant reduction in the incidence of infectious complications among patients who received early enteral nutrition (25 versus 41 percent, relative risk 0.66, 95% CI 0.36-1.22) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9\">",
"     9",
"    </a>",
"    ]. In an unpublished update of the meta-analysis, seven randomized trials (440 additional patients) were added and the reduction in the incidence of infectious complications became statistically significant (43 versus 58 percent, relative risk 0.76, 95% CI 0.59-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/12\">",
"     12",
"    </a>",
"    ]. These meta-analyses are limited by the methodological flaws of the included randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms by which enteral nutrition decreases infectious complications are unknown. However, preservation of gut immune function and reduction of inflammation have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether early enteral nutrition decreases mortality in critically ill patients is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9,12,16\">",
"     9,12,16",
"    </a>",
"    ]. In a meta-analysis of eight randomized trials (317 patients) that compared early enteral nutrition to either delayed enteral nutrition or intravenous fluids, there was a non-statistically significant mortality reduction among the patients who received early enteral nutrition (6 versus 15 percent, relative risk 0.52, 95% CI 0.25-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9\">",
"     9",
"    </a>",
"    ]. In an unpublished update of the meta-analysis, 14 randomized trials (670 additional patients) were added [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/12\">",
"     12",
"    </a>",
"    ]. The reduction of mortality was almost statistically significant (10 versus 20 percent, relative risk 0.68, 95% CI 0.46-1.01).",
"   </p>",
"   <p>",
"    In summary, the evidence supports a clinically important and statistically significant reduction in infection when enteral nutrition is administered early to critically ill patients, as well as a clinically important and almost statistically significant reduction in mortality. Based upon these observations, we believe that the potential benefit of early enteral nutrition outweighs the likelihood of harm and that it should be prescribed for most critically ill patients who do not have contraindications to enteral feeding. We recognize that the evidence for this approach is higher quality for patients with surgical problems than medical problems: surgical patients (eg, trauma, peritonitis, pancreatitis, and burns) were the focus of the randomized trials and meta-analyses described above [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9,12\">",
"     9,12",
"    </a>",
"    ], whereas medical patients have primarily been studied in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935231\">",
"    <span class=\"h3\">",
"     Parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that early parenteral nutrition (usually defined as within 48 hours) improves clinical outcomes in critically ill patients, but there is evidence that it may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. This was best illustrated by a meta-analysis of 69 randomized trials (3750 patients) that compared the outcomes of patients who received parenteral nutrition to those who received either no nutrient intake or only dextrose-containing intravenous fluids found no favorable difference in mortality or any other clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients who received parenteral nutrition had a 5 percent increase in the incidence of infection.",
"   </p>",
"   <p>",
"    The use of parenteral nutrition as an adjunct to enteral nutrition (to improve provision of calories and protein) has also been evaluated and at least two studies suggest that this strategy may be harmful. The first study was a multicenter trial that randomly assigned 4640 critically ill adults who were already receiving enteral nutrition to have supplemental parenteral nutrition initiated early (within 48 hours of ICU admission) or late (after the eighth day of ICU admission) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/19\">",
"     19",
"    </a>",
"    ]. Those who received early parenteral nutrition were more likely to develop a new infection and had a longer duration of mechanical ventilation, ICU stay, and hospitalization. The second study was an observational study that compared three groups: enteral nutrition alone, enteral nutrition plus early parenteral nutrition, and enteral nutrition plus late parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/20\">",
"     20",
"    </a>",
"    ]. Enteral nutrition plus either early or late parenteral nutrition was associated with increased mortality compared to enteral nutrition alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935240\">",
"    <span class=\"h3\">",
"     Enteral versus parenteral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct comparisons of enteral nutrition to parenteral nutrition indicate that enteral nutrition is associated with a lower incidence of infection, but not mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection &ndash; A meta-analysis of six randomized trials (498 patients) found that patients who received enteral nutrition were significantly less likely to develop an infection than patients who received parenteral (24 versus 43 percent, relative risk 0.61, 95% CI 0.44-0.84) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality &ndash; A meta-analysis of 12 randomized trials (748 patients) found no difference in mortality among patients who received enteral nutrition compared to those who received parenteral nutrition [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both meta-analyses, the majority of patients had surgical problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935249\">",
"    <span class=\"h2\">",
"     Malnourished patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials have excluded malnourished patients. In clinical practice, however, malnourishment may exist at the time of admission or as a consequence of receiving little or no nutritional intake for an extended period (eg, two weeks) during the hospitalization. We believe that enteral nutrition is beneficial to such patients, since it is well established that chronic starvation is deleterious. Some clinicians also cite observational evidence that a progressive caloric deficit is associated with increased morbidity in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/7\">",
"     7",
"    </a>",
"    ], as well as the indirect evidence described above from adequately nourished patients. The effect of parenteral nutrition on malnourished patients is unknown but being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of enteral nutrition are aspiration, diarrhea, metabolic abnormalities, and mechanical complications. These complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link&amp;anchor=H26#H26\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common complications of parenteral nutrition are bloodstream infection, metabolic abnormalities, and problems related to venous access. These complications are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link&amp;anchor=H12#H12\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our usual approach to selecting critically ill patients for nutrition support is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without contraindications to enteral nutrition, we begin early enteral feeding (ie, within 48 hours) because we believe that the potential benefits of early enteral feeding (eg, fewer infections, possibly lower mortality) outweigh its risks [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/9,11,12,23\">",
"       9,11,12,23",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H935222\">",
"       'Enteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adequately nourished patients who have contraindications to enteral nutrition, we do NOT initiate early parenteral nutrition. This reflects the evidence that early parenteral nutrition may increase the risk of infection and prolong mechanical ventilation, ICU stay, and hospital stay [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H935231\">",
"       'Parenteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For malnourished patients who have contraindications to enteral nutrition, we initiate parenteral nutrition. We recognize that the effects of parenteral nutrition in such patients are unknown; however, our rationale is that failure to treat the malnourishment will result in a progressive caloric deficit, which is associated with increased morbidity. (See",
"      <a class=\"local\" href=\"#H935249\">",
"       'Malnourished patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence that a patient is malnourished includes poor nutritional intake accompanied by unintentional weight loss or low body weight. Sample criteria (arbitrarily chosen and not validated) include a body mass index (BMI) less than 18.5",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    the unintentional loss of more than 2.3 kg (5 lb) or 5 percent of body weight over one month, or the unintentional loss of more than 4.5 kg (10 lb) or 10 percent of body weight over six months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/24\">",
"     24",
"    </a>",
"    ]. Temporal muscle wasting, sunken supraclavicular fossae, decreased adipose stores, and signs of vitamin deficiencies may also be apparent (",
"    <a class=\"graphic graphic_table graphicRef78426 \" href=\"UTD.htm?1/19/1341\">",
"     table 1",
"    </a>",
"    ). &nbsp;While such findings may be suggestive of malnutrition, they are imperfect because they are just as likely to be a consequence of the catabolic effect of the underlying illness. Nutritional surrogates (eg, albumin,",
"    <span class=\"nowrap\">",
"     prealbumin/transthyretin)",
"    </span>",
"    are also susceptible to the effects of the critical illness and should not be used to detect malnourishment in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/25\">",
"     25",
"    </a>",
"    ]. A list of nutrients and clinical manifestations due to their excess or deficiency is available at",
"    <a class=\"external\" href=\"file://www.nal.usda.gov/wicworks/Topics/FG/AppendixC_NutrientChart.pdf\">",
"     file://www.nal.usda.gov/wicworks/Topics/FG/AppendixC_NutrientChart.pdf",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It is assumed that malnutrition is impending when there has been a prolonged period of poor nutritional intake. The precise duration necessary for malnutrition to develop is unknown and probably varies among patients. As a general guideline, it is reasonable to assume that malnutrition is impending in any patient who has had little or no nutritional intake for two weeks. One week or less may be more accurate for patients with antecedent undernourishment, with the precise duration depending on the severity of the undernourishment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early enteral nutrition is contraindicated in critically ill patients who are both hemodynamically unstable and have not had their intravascular volume fully resuscitated, since such patients may be predisposed to bowel ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/1\">",
"     1",
"    </a>",
"    ]. Hemodynamic instability by itself, unless severe, is not a contraindication for enteral nutrition if there is evidence for adequate volume resuscitation and tissue perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/26\">",
"     26",
"    </a>",
"    ]. Other contraindications to enteral nutrition include bowel obstruction, severe and protracted ileus, major upper gastrointestinal bleeding, intractable vomiting or diarrhea, severe hemodynamic instability, gastrointestinal ischemia, and a high output fistula.",
"   </p>",
"   <p>",
"    Some conditions previously considered contraindications to enteral nutrition are no longer considered as such. Examples include hyperemesis gravidarum and the absence of bowel sounds or flatus following routine colorectal surgery or surgery for bowel perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/8,27-31\">",
"     8,27-31",
"    </a>",
"    ]. While such patients remain at increased risk for vomiting, enteral nutrition may confer an overall benefit since it may decrease the risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/8,30\">",
"     8,30",
"    </a>",
"    ]. In addition, a new gastrointestinal anastomosis distal to the infusion site that the surgeon feels is at risk of dehiscence was once considered a contraindication until more recent data indicated that early feeding strengthens anastomoses.",
"   </p>",
"   <p>",
"    Contraindications to parenteral nutrition include hyperosmolality, severe hyperglycemia, severe electrolyte abnormalities, volume overload, and inadequate attempts to feed enterally. Sepsis or systemic inflammatory response syndrome is a relative contraindication to parenteral nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NUTRITIONAL REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been determined that a critically ill patient will receive nutrition support, the patient's nutritional requirements must be determined. These requirements are used to select the appropriate formulation and rate of administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials evaluating the optimal quantity of caloric intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protein intake are unlikely to be performed with adequate precision because the anticipated sample sizes required to detect outcome differences are prohibitively large. Small trials have been performed, but their results are equivocal. Trials that compare the measurement of caloric or protein intake to the estimation of caloric or protein intake (eg, formulas, tables) are similarly unlikely to be performed. Thus, clinical decisions must be based upon observational evidence and clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dosing weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;When prescribing enteral or parenteral nutrition, the appropriate body weight from which to calculate caloric and protein intake (ie, the dosing weight) must first be determined.",
"   </p>",
"   <p>",
"    For patients who are underweight (body mass index [BMI] &lt;18.5",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    we suggest using the current weight as the initial dosing weight. The reason is that calculation of caloric intake based on ideal body weight could lead to the administration of excess calories and induce refeeding syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H252082#H252082\">",
"     \"Eating disorders: Treatment\", section on 'Refeeding syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients whose weight is normal (BMI 18.5 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or who are overweight (BMI 25 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    we suggest using the current weight as the dosing weight. An effort should be made to subtract the estimated weight of any peripheral edema.",
"   </p>",
"   <p>",
"    For patients who are obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    we suggest that the dosing weight be adjusted. The purpose of adjusting the dosing weight of patients who are obese is to account for the absence of metabolic requirements by fat tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most commonly employed method is to add one-quarter of the difference between the ideal body weight (IBW) and the actual body weight (ABW) to the IBW. In other words, dosing weight = IBW + 0.25 (ABW - IBW).",
"     </li>",
"     <li>",
"      An alternative method is to use 110 percent of the ideal body weight. In other words, dosing weight = 1.1 * IBW.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For either equation, the IBW can be determined from the calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Calories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians have the challenge of finding the amount of calories that is sufficient to meet the metabolic needs of the patient, without being excessive. Initially underfeeding patients who are critically ill is controversial, but there is some evidence that it may improve clinical outcomes (eg, less gastrointestinal intolerance, fewer infections) and it has become our practice [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13831/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. We believe that a safe starting point for most critically ill patients is 18",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day, although this target has not been rigorously validated. Attempting to achieve a goal of 25 to 30",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day within one week is reasonable for most stable patients. A goal of 35",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day is an acceptable goal if weight gain is desired in a relatively stable patient; weight gain should not be attempted until the patient is stable and in a lower inflammatory state. We keep the caloric goal at 25",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day or less if extubation is imminent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein requirements increase as illness becomes more severe. Thus, patients with only mild to moderate illness require only 0.8 to 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. Critically ill patients generally require 1.2 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day and patients with severe burns may need as much as 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of nutrition support requires that appropriate access is to be established and that the composition and rate of delivery be determined. Once started, nutrition support must be monitored for tolerance and complications. These issues are different for enteral and parenteral nutrition, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nutrition support refers to the enteral or parenteral provision of calories, protein, electrolytes, vitamins, minerals, and fluids. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Critically ill patients are selected for nutrition support on the basis of whether they have contraindications to enteral nutrition, as well as whether the patient is adequately nourished or malnourished:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For critically ill surgical patients without contraindications to enteral nutrition, we recommend early (eg, within 48 hours) enteral nutrition (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For critically ill medical patients without contraindications to enteral nutrition, we suggest early enteral nutrition (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H935222\">",
"       'Enteral nutrition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adequately nourished patients who have contraindications to enteral nutrition, we recommend NOT initiating early parenteral nutrition (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H935231\">",
"       'Parenteral nutrition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For malnourished patients who have contraindications to enteral nutrition that are expected to persist one week or less, we suggest NOT initiating parenteral nutrition (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For malnourished patients who have contraindications to enteral nutrition that are expected to persist greater than one week, we suggest parenteral nutrition (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H935249\">",
"       'Malnourished patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acceptable initial nutritional goal is 18 kcal of",
"      <span class=\"nowrap\">",
"       calories/kg",
"      </span>",
"      per day and 1.5 grams of",
"      <span class=\"nowrap\">",
"       protein/kg",
"      </span>",
"      per day, although these targets have not been rigorously validated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nutritional requirements'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/1\">",
"      McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009; 33:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/2\">",
"      Shaw JH, Koea JB. Metabolic basis for management of the septic surgical patient. World J Surg 1993; 17:154.",
"     </a>",
"    </li>",
"    <li>",
"     Babineau TJ, Borlase BC, Blackburn GL. Applied Total Parental Nutrition in the Critically Ill. In: Intensive Care Medicine, Rippe JM, Irwin RS, Alpert JS, Fink MP (Eds), Little, Brown and Co, Boston 1991. p.1675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/4\">",
"      Wanzer SH, Federman DD, Adelstein SJ, et al. The physician's responsibility toward hopelessly ill patients. A second look. N Engl J Med 1989; 320:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/5\">",
"      Nordenstr&ouml;m J, Carpentier YA, Askanazi J, et al. Free fatty acid mobilization and oxidation during total parenteral nutrition in trauma and infection. Ann Surg 1983; 198:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/6\">",
"      Plank LD, Connolly AB, Hill GL. Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann Surg 1998; 228:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/7\">",
"      Dvir D, Cohen J, Singer P. Computerized energy balance and complications in critically ill patients: an observational study. Clin Nutr 2006; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/8\">",
"      Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 2001; 29:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/9\">",
"      Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355.",
"     </a>",
"    </li>",
"    <li>",
"     Early vs Delayed Nutrient Intake. file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on January 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/11\">",
"      Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.",
"     </a>",
"    </li>",
"    <li>",
"     Early vs. Delayed nutrient intake file://www.criticalcarenutrition.com/docs/cpg/2.0early_FINAL.pdf (Accessed on August 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/13\">",
"      Koretz RL. Enteral nutrition: a hard look at some soft evidence. Nutr Clin Pract 2009; 24:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/14\">",
"      McClave SA, Heyland DK. The physiologic response and associated clinical benefits from provision of early enteral nutrition. Nutr Clin Pract 2009; 24:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/15\">",
"      Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003; 31:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/16\">",
"      Heyland DK, Cahill N, Day AG. Optimal amount of calories for critically ill patients: depends on how you slice the cake! Crit Care Med 2011; 39:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/17\">",
"      Artinian V, Krayem H, DiGiovine B. Effects of early enteral feeding on the outcome of critically ill mechanically ventilated medical patients. Chest 2006; 129:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/18\">",
"      Koretz RL, Lipman TO, Klein S, American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/19\">",
"      Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/20\">",
"      Kutsogiannis J, Alberda C, Gramlich L, et al. Early use of supplemental parenteral nutrition in critically ill patients: results of an international multicenter observational study. Crit Care Med 2011; 39:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/21\">",
"      Cahill NE, Murch L, Jeejeebhoy K, et al. When early enteral feeding is not possible in critically ill patients: results of a multicenter observational study. JPEN J Parenter Enteral Nutr 2011; 35:160.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/NCT01206166 (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/23\">",
"      Gramlich L, Kichian K, Pinilla J, et al. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition 2004; 20:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/24\">",
"      Blackburn GL, Bistrian BR, Maini BS, et al. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enteral Nutr 1977; 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/25\">",
"      Seres DS. Surrogate nutrition markers, malnutrition, and adequacy of nutrition support. Nutr Clin Pract 2005; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/26\">",
"      Khalid I, Doshi P, DiGiovine B. Early enteral nutrition and outcomes of critically ill patients treated with vasopressors and mechanical ventilation. Am J Crit Care 2010; 19:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/27\">",
"      Bufo AJ, Feldman S, Daniels GA, Lieberman RC. Early postoperative feeding. Dis Colon Rectum 1994; 37:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/28\">",
"      Reissman P, Teoh TA, Cohen SM, et al. Is early oral feeding safe after elective colorectal surgery? A prospective randomized trial. Ann Surg 1995; 222:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/29\">",
"      Kaur N, Gupta MK, Minocha VR. Early enteral feeding by nasoenteric tubes in patients with perforation peritonitis. World J Surg 2005; 29:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/30\">",
"      Andersen HK, Lewis SJ, Thomas S. Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications. Cochrane Database Syst Rev 2006; :CD004080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/31\">",
"      Mentec H, Dupont H, Bocchetti M, et al. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med 2001; 29:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/32\">",
"      Kraft MD, Btaiche IF, Sacks GS. Review of the refeeding syndrome. Nutr Clin Pract 2005; 20:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/33\">",
"      Ibrahim EH, Mehringer L, Prentice D, et al. Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. JPEN J Parenter Enteral Nutr 2002; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13831/abstract/34\">",
"      Rice TW, Mogan S, Hays MA, et al. Randomized trial of initial trophic versus full-energy enteral nutrition in mechanically ventilated patients with acute respiratory failure. Crit Care Med 2011; 39:967.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1617 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13831=[""].join("\n");
var outline_f13_32_13831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2782159\">",
"      Adequately nourished patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935222\">",
"      - Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935231\">",
"      - Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935240\">",
"      - Enteral versus parenteral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H935249\">",
"      Malnourished patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NUTRITIONAL REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dosing weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Calories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/19/1341\" title=\"table 1\">",
"      Signs of nutritional deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=related_link\" title=\"calculator 1\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=related_link\">",
"      Nutrition support in critically ill patients: Parenteral nutrition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13832="Clinical manifestations and diagnosis of polymyalgia rheumatica";
var content_f13_32_13832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of polymyalgia rheumatica",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13832/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13832/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13832/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13832/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/32/13832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized clinically by aching and morning stiffness in the shoulders, hip girdle, and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ]. It can be associated with giant cell (temporal) arteritis (GCA), and the two disorders may represent different manifestations of a shared disease process.",
"   </p>",
"   <p>",
"    As a result of this association, there are two main issues that arise when PMR is considered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How is the diagnosis established and distinguished from other disorders that can produce similar symptoms?",
"     </li>",
"     <li>",
"      Does the patient also have GCA?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PMR is two to three times more common than GCA. PMR occurs in about 50 percent of patients with GCA, while approximately 15 to 30 percent of patients with PMR eventually develop GCA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some patients have manifestations of both disorders occurring at different times.",
"   </p>",
"   <p>",
"    The major features of PMR, with emphasis on clinical manifestations and diagnosis, will be reviewed here. Issues related to the treatment of PMR and to GCA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40598?source=see_link\">",
"     \"Treatment of polymyalgia rheumatica\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyalgia rheumatica (PMR) is almost exclusively a disease of adults over the age of 50, with prevalence that increases progressively with advancing age. The average age at diagnosis is over 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PMR is relatively common, with a prevalence of about 700 per 100,000 persons over 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/4\">",
"     4",
"    </a>",
"    ]. Women are affected two to three times more often than are men.",
"   </p>",
"   <p>",
"    The annual incidence varies geographically [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In Europe, for example, the incidence rates are highest in northern regions (113 per 100,000 per year in Norway) and much lower in southern areas (13 per 100,000 per year in Italy) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/5\">",
"     5",
"    </a>",
"    ]. Rates in Japan are even lower than Europe (less than 2 per 100,000 patients older than 50) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of PMR is unknown; both environmental and genetic factors appear to play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. In addition to the frequent clinical association between PMR and GCA, there is also evidence of a pathogenetic similarity between the two disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8166?source=see_link\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both PMR and GCA are associated with specific alleles of HLA-DR4. In addition, there is a sequence polymorphism within the hypervariable region of the HLA-DRB1 gene that maps to the antigen-binding cleft of the HLA-DR molecules, suggesting an important role for antigen selection and presentation. Patients with GCA and PMR share this sequence polymorphism, which is not shared by patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although pathological findings in PMR are less prominent than in GCA, a mild synovitis characterized by macrophages and CD4+ T lymphocytes has been described in synovial membranes from involved joints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ]. Evidence of subclinical arterial inflammation can be detected in some patients, including the presence of activated dendritic cells, interleukin-1, and interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ]. However, unlike GCA, interferon gamma producing T cells are not prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies of PMR and GCA have suggested a cyclical pattern in incidence and seasonal variation, indicating a possible environmental infectious trigger [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/3\">",
"     3",
"    </a>",
"    ]. Results of studies of several viruses as potential triggers have been inconclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMR is typically characterized by the subacute or chronic onset of aching and morning stiffness in the shoulders, hip girdles, neck, and torso in patients over the age of 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. The symptoms are usually symmetric [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following features can be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stiffness &mdash; Morning stiffness typically lasts at least 30 minutes. Difficulty with activities related to the shoulder and hip stiffness may be described by the patient as trouble dressing (eg, fastening a bra normally, donning a shirt or jacket, or pulling on stockings). In some patients, stiffness may be so severe that rising from or turning over in bed represent major obstacles.",
"     </li>",
"     <li>",
"      Pain &mdash; Shoulder pain is more common at presentation (70 to 95 percent of patients) than is hip and neck involvement (50 to 70 percent). Pain is worse with movement and may interfere with sleep.",
"     </li>",
"     <li>",
"      Synovitis and bursitis &mdash; About half of patients exhibit distal musculoskeletal manifestations. Palpable synovitis appears to occur in more peripheral joints, such as the knees, wrists, and metacarpophalangeal joints [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Synovitis is usually mild and nonerosive, and may be asymmetric.",
"      <br/>",
"      <br/>",
"      Synovitis and bursitis are thought to be the causes of the discomfort and stiffness. However, because the shoulders and hips are surrounded by large muscles, small amounts of synovitis in these joints are not readily detected on physical examination.",
"     </li>",
"     <li>",
"      Swelling and tenosynovitis &mdash; Some patients develop swelling and pitting edema of the hands, wrists, ankles, and top of the feet [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/10,13\">",
"       10,13",
"      </a>",
"      ]. The edema usually occurs with other signs of PMR, but can be the presenting symptom. It appears to represent tenosynovitis and synovitis in regional structures [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/13\">",
"       13",
"      </a>",
"      ]. Tenosynovitis can also cause carpal tunnel syndrome, which occurs in approximately 10 to 15 percent of patients with PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased range of motion &mdash; There may be decreased active, and sometimes passive, range of motion of the shoulders, neck, and hips.",
"     </li>",
"     <li>",
"      Muscle tenderness &mdash; Despite the implications of the name \"polymyalgia,\" muscle tenderness is not a prominent feature, and what tenderness there may be about the shoulders is more likely due to synovial or bursal inflammation than muscle involvement.",
"     </li>",
"     <li>",
"      Subjective weakness &mdash; Muscle strength is usually normal. However, weakness is often reported by patients and may be a problem diagnostically due to diminished effort on examination because of pain, or clinically because of disuse atrophy. Thus, careful testing is required if weakness is reported.",
"     </li>",
"     <li>",
"      Systemic signs and symptoms &mdash; Up to 40 percent of patients experience systemic signs or symptoms, including malaise, fatigue, depression, anorexia, weight loss, and fever. However, the high spiking fever that can sometimes occur in GCA is rare in patients who have only PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic laboratory finding in PMR (and in GCA) is an erythrocyte sedimentation rate (ESR) that is above 40",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    (78 to 93 percent in some series), with some patients having values that can exceed 100",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In one study, 20 percent of patients had ESR values over 104",
"    <span class=\"nowrap\">",
"     mm/hr",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/17\">",
"     17",
"    </a>",
"    ]. Levels below 40",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    are most likely to occur in patients with limited disease and fewer systemic symptoms and in those who have been treated with glucocorticoids.",
"   </p>",
"   <p>",
"    Some evidence suggests that an elevated serum C-reactive protein (CRP) level is more common than a high ESR. In two reports from the same group, an elevated ESR (greater than 30",
"    <span class=\"nowrap\">",
"     mm/h)",
"    </span>",
"    was noted in 92 to 94 percent of patients at the time of diagnosis of PMR, while 99 percent of such patients had an increased serum CRP level (greater than 5",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In one of these studies, nine of the ten patients with a normal ESR at time of diagnosis had an elevated CRP (median 14",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    range 7 to 47",
"    <span class=\"nowrap\">",
"     mg/L),",
"    </span>",
"    although mean values tended to be lower than in the group as a whole (19 versus 68",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/17\">",
"     17",
"    </a>",
"    ]. Among patients with PMR, 90 percent had an ESR greater than 40",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    and 90 percent had a CRP greater than 22",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"   </p>",
"   <p>",
"    Other laboratory findings are nonspecific:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normocytic anemia may be present, and the white blood cell and platelet counts are usually normal. In some patients, however, the platelet count is increased as part of a general inflammatory response.",
"     </li>",
"     <li>",
"      Serologic tests, such as antinuclear antibodies, rheumatoid factor, and cyclic citrullinated peptide antibodies are typically negative [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients experience an increase in liver enzymes, especially alkaline phosphatase, although this is more common in patients with GCA than PMR alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine radiographs of inflamed joints rarely reveal any abnormalities in patients with PMR. By comparison, routine imaging by other techniques (such as magnetic resonance imaging or ultrasonography) can detect underlying inflammation in patients with PMR. However, this is usually not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     MRI and ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) studies have confirmed that PMR involves inflammation of extraarticular synovial structures. As an example, MRI of the hands and feet of affected patients frequently demonstrates inflammation of the tenosynovial sheaths; flexor, posterior tibial, and peroneal tenosynovitis have also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, shoulder MRI reveals subacromial and subdeltoid bursitis (typically bilateral) in almost all patients with active PMR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bursa ultrasonography (US) often reveals effusions within both shoulder bursae in patients with PMR. In a case-control study of 57 patients with untreated PMR and 114 control individuals with bilateral shoulder aching and stiffness, US detected bilateral",
"    <span class=\"nowrap\">",
"     subacromial/subdeltoid",
"    </span>",
"    bursitis in most patients but few controls (96 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, there was no difference between the groups in the incidence of glenohumeral joint synovitis or biceps tenosynovitis. There was a good correlation between US and MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET scanning) has no proven clinical value in the care of patients with PMR, but has been of interest in the investigation of underlying vascular involvement. Data are limited on PET scanning in patients with PMR. In a series of 13 patients with suspected PMR who underwent 18-fluorodeoxyglucose PET scanning prior to initiation of glucocorticoid therapy, 12 had increased uptake in vascular regions as assessed by visual inspection of the images and by a computer aided quantitative analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/21\">",
"     21",
"    </a>",
"    ]. While increased uptake of radiolabeled glucose is suggestive of large vessel vasculitis, histologic examination of the aorta and large arteries was not feasible.",
"   </p>",
"   <p>",
"    The clinical implications of these PET scan findings are unclear, although they may indicate that subclinical inflammation of the great vessels is more common than previously supposed in PMR. Further study is needed to determine whether PET scanning has any prognostic or therapeutic implications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important elements in the evaluation of the patient suspected of having PMR include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focusing on key elements that are consistent with the diagnosis",
"     </li>",
"     <li>",
"      Careful attention to the possible presence of disorders that closely resemble PMR",
"     </li>",
"     <li>",
"      Particular attention to the possible presence of GCA, which is found in 15 to 30 percent of those with PMR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial evaluation of patients suspected of having PMR includes a complete history and physical, as well as selected laboratory testing. We suggest particular attention to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful questioning concerning the presence of truncal, shoulder, and hip stiffness and pain; morning stiffness (at least 30 minutes); joint pain and swelling; muscle pain and weakness; disruption of sleep; and systemic symptoms (eg, fever and weight loss). The history should also include whether there are symptoms of GCA, including new headache, jaw claudication, scalp tenderness, visual change, fever, or cough. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms and signs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation for GCA'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A review of systems to elicit a history that may suggest another disorder to explain the symptoms. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Complete musculoskeletal examination to assess range of motion in the truncal and peripheral joints and spine; the presence of signs of inflammatory or degenerative arthritis, tendonitis or bursitis; and muscle strength and tenderness. Patients should be examined for evidence of tender points suggestive of fibromyalgia and other findings that may also support an alternative diagnosis, such as hypothyroidism or Parkinson disease. The temporal arteries should be examined for signs of inflammation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms and signs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation for GCA'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Laboratory testing should include a CBC and platelet count, erythrocyte sedimentation rate, and CRP levels. Additional testing may be required depending upon the patient's symptoms and findings and other diagnoses being considered. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Imaging studies such as an MRI or ultrasound of the shoulder region may be useful to determine if an inflammatory process is present in patients with signs and symptoms of PMR, but a normal ESR and CRP, if uncertainty remains regarding the diagnosis. Plain radiographs are not required, unless another diagnosis that may be confirmed or excluded by such studies is being considered. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis of PMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of any pathognomonic test, we use the presence of each of the following three criteria for the clinical diagnosis of PMR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age 50 years or older at disease onset",
"     </li>",
"     <li>",
"      Bilateral aching and morning stiffness (lasting 30 minutes or more) persisting for at least one month. The stiffness should involve at least two of the following three areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (Westergren) &ge;40",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts add a prompt response of symptoms to glucocorticoids as an additional criterion. Symptoms are generally 50 to 70 percent better within three days in patients with PMR started on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    The presence of another disease to explain the findings excludes the diagnosis.",
"   </p>",
"   <p>",
"    Establishing the diagnosis is more difficult in patients with atypical presentations. These include age 40 to 50 years, asymmetric symptoms, and ESR less than 40",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/2,14-16\">",
"     2,14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In younger patients, inflammatory rheumatic diseases that may mimic PMR are more prevalent than PMR itself; the diagnosis in these patients thus necessitates careful consideration of alternative diagnoses [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Asymmetric symptoms may be present especially early in disease, beginning in one shoulder or hip, but soon become bilateral in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although there is less experience with use of serum CRP testing to establish the diagnosis of PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/17\">",
"       17",
"      </a>",
"      ], it may be reasonable to substitute an elevated serum CRP (above the upper limit of normal for the testing laboratory) as a criterion for PMR if the ESR is less than 40",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      because of the higher sensitivity of CRP elevation than an abnormal ESR. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Evaluation for GCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there is considerable overlap in the diagnoses of PMR and GCA. Patients with \"pure\" PMR lack the classic findings of GCA such as temporal artery tenderness, headache, jaw pain, visual loss, and evidence of noncranial ischemia (such as arm claudication or cerebral ischemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/12\">",
"     12",
"    </a>",
"    ]. In the absence of such signs or symptoms, we do NOT routinely perform a temporal artery biopsy, since a positive result is rare in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/12,23\">",
"     12,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a marked inflammatory response, such as a high fever (at least 39&ordm;C) or a lack of response to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may have an abnormal temporal artery biopsy if performed. However, we do not routinely biopsy such patients since they seldom develop ischemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest ongoing monitoring for symptoms or physical findings suggestive of GCA in patients with PMR. Evaluation including biopsy should be performed if symptoms of GCA develop, even if patients are on glucocorticoids. The yield of temporal artery biopsy does not appear to be affected by previous glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40598?source=see_link\">",
"     \"Treatment of polymyalgia rheumatica\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PMR includes early seronegative rheumatoid arthritis (RA) (most common) and a large variety of other disorders that can usually be easily distinguished clinically from PMR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/1,2,22\">",
"     1,2,22",
"    </a>",
"    ]. Limited laboratory testing may be helpful depending on the specific clinical presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rheumatoid arthritis",
"      </strong>",
"      &mdash; Patients with RA usually have symmetric polyarthritis of the small joints of the hands and feet, which is persistent and only partially responsive to low doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . These findings are different from that in PMR in which fewer joints are swollen, and the swelling subsides completely in response to low dose prednisone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"       \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There is, however, considerable overlap between PMR and seronegative RA in elderly subjects who present with a benign symmetric synovitis. &nbsp;The following are illustrative:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a report of 159 such patients, synovitis was recurrent in 57, 20 of whom had one episode that looked like PMR and another that looked like RA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/25\">",
"       25",
"      </a>",
"      ]. All patients responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . Twenty-four patients later developed GCA: 19 had been given the diagnosis of PMR and 5 of RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another study compared 142 patients with late-onset (over the age of 60) seronegative (rheumatoid factor negative) RA, 147 with PMR, and 42 with PMR-GCA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/26\">",
"       26",
"      </a>",
"      ]. Patients were followed for a minimum of five years. Although synovitis was present at baseline in 23 percent of patients with PMR, what helped distinguish one from the other at baseline were the following: patients with PMR all had myalgia, while the presence of MCP, PIP,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wrist involvement was more suggestive of RA; furthermore, the synovitis generally responded quickly to treatment with glucocorticoids and did not require treatment with disease-modifying antirheumatic drugs. Acute phase reactants (ESR, CRP, IL-6) were higher in patients with PMR and responded more dramatically to treatment with glucocorticoids than in patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We initially treat those patients in whom PMR cannot be clinically distinguished from seronegative RA with glucocorticoids in the doses used for PMR, and observe the response over the first two months of therapy. Patients who respond well to such therapy are continued on this treatment regimen and glucocorticoids are tapered accordingly. Treatment for RA should be instituted instead if symptoms of arthritis respond incompletely or evolve in a pattern more characteristic of RA during initial glucocorticoid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40598?source=see_link\">",
"       \"Treatment of polymyalgia rheumatica\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       RS3PE syndrome",
"      </strong>",
"      &mdash; The symptoms and signs of the RS3PE syndrome (",
"      <strong>",
"       r",
"      </strong>",
"      emitting",
"      <strong>",
"       s",
"      </strong>",
"      eronegative",
"      <strong>",
"       s",
"      </strong>",
"      ymmetrical",
"      <strong>",
"       s",
"      </strong>",
"      ynovitis with",
"      <strong>",
"       p",
"      </strong>",
"      itting",
"      <strong>",
"       e",
"      </strong>",
"      dema) may be mistaken for those of PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients with RS3PE typically have the sudden onset of polyarthritis, are frequently over 50 years of age, and lack rheumatoid factor. Symptoms are usually more prominent distally, unlike PMR. Some patients with this disorder respond to treatment with low-dose glucocorticoids and may be considered to have a variant of PMR with prominent edema. Others can evolve into a more specific disease such as RA or a spondyloarthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some patients with RS3PE have a paraneoplastic disorder that is associated with solid tumors and hematologic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/30\">",
"       30",
"      </a>",
"      ]. The possibility of malignancy may be increased in those who do not have a favorable response to low-dose glucocorticoid therapy.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Bursitis/tendinitis",
"       </strong>",
"      </span>",
"      &mdash; The symptoms and findings in the shoulders in PMR may be similar to subdeltoid bursitis without PMR or rotator cuff tendinitis. However, tenderness is minimal in most cases of PMR, while patients with bursitis or tendinitis alone lack constitutional symptoms, an elevated erythrocyte sedimentation rate, anemia, and bilateral shoulder involvement. Despite these general differences, a form of subacromial and subdeltoid bursitis as well as shoulder synovitis may underlie the shoulder girdle stiffness in PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'MRI and ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Spondyloarthropathy",
"      </strong>",
"      &mdash; Proximal symptoms similar to PMR can be seen in patients with late onset spondyloarthropathy (SpA) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/31\">",
"       31",
"      </a>",
"      ]. Axial skeletal involvement, oligoarthritis, distal pitting edema, and constitutional symptoms, such as fever, anorexia, and weight loss may be present along with an elevated ESR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/32\">",
"       32",
"      </a>",
"      ]. SpA and PMR can be distinguished in these patients by the presence of other findings typical of SpA, but not PMR, such as enthesitis, dactylitis, anterior uveitis, sacroiliitis on imaging, and the greater prevalence of HLA-B27. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       CPPD disease",
"      </strong>",
"      &mdash; Patients with polyarticular calcium pyrophosphate deposition disease (CPPD) infrequently present with symptoms suggestive of PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/33\">",
"       33",
"      </a>",
"      ]. The diagnosis of CPPD disease is made by the identification of characteristic crystals on examination of the joint fluid. Radiographic findings, such as chondrocalcinosis, may also be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypothyroidism",
"      </strong>",
"      &mdash; Patients with hypothyroidism may present with aching, stiffness, and arthralgias. Slow relaxation of deep tendon reflexes, a low serum thyroxine (T4) concentration, and an elevated serum thyrotropin (TSH) concentration are characteristic of hypothyroidism and are not seen in PMR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations of hypothyroidism\", section on 'Musculoskeletal symptoms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fibromyalgia",
"      </strong>",
"      &mdash; Patients with fibromyalgia syndrome (FMS) experience widespread musculoskeletal pain, stiffness, aching, and fatigue. Although such patients are often younger than 50 years, FMS can be seen in older patients. No obvious abnormalities on physical examination other than characteristic tender points may be present in patients with FMS, and unlike most patients with PMR, those with FMS have a normal erythrocyte sedimentation rate, C-reactive protein, and hematocrit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy",
"      </strong>",
"      &mdash; There is no association between the occurrence of PMR alone and malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/34\">",
"       34",
"      </a>",
"      ]. However, occasional patients with malignancy have a paraneoplastic syndrome with diffuse muscle and joint pains that can mimic PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/2,35\">",
"       2,35",
"      </a>",
"      ]. These patients do not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      but do respond to removal of the tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H16#H16\">",
"       \"Malignancy and rheumatic disorders\", section on 'Malignant diseases: Musculoskeletal manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Multiple myeloma can present with bone pain and an elevated ESR, thereby mimicking PMR. Such patients can be identified by the presence of a monoclonal protein in the serum or urine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Infective endocarditis",
"      </strong>",
"      &mdash; Endocarditis and other infectious diseases may occasionally mimic PMR. Persistent fever may suggest the possible diagnosis of infective endocarditis. The presence of a heart murmur, positive blood cultures, and vegetation on a heart valve on echocardiography are the diagnostic features of this infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Inflammatory myopathy",
"      </strong>",
"      &mdash; Patients with dermatomyositis or polymyositis present with symmetric proximal muscle weakness, and shoulder or hip pain is not as prominent as in PMR. Elevated muscle enzymes, abnormal electromyography, and evidence of myositis on muscle biopsy establish the diagnosis of an inflammatory myopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vasculitis",
"      </strong>",
"      &mdash; Vasculitic disorders other than GCA can present with arthralgia and an elevated ESR. This was illustrated in a retrospective study of 86 patients with systemic vasculitis affecting small vessels, 11 (13 percent) were thought to have PMR prior to the recognition of renal involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/36\">",
"       36",
"      </a>",
"      ]. All 11 were found to have antineutrophil cytoplasmic antibodies (ANCA). Clinical and laboratory features that suggest ANCA-associated vasculitis include symptoms of upper respiratory tract involvement, pulmonary hemorrhage, renal disease, and neuropathy and positive ANCA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; Other conditions in which the ESR is normal may occasionally be mistaken for PMR [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13832/abstract/22\">",
"       22",
"      </a>",
"      ]. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Parkinson disease",
"      </strong>",
"      &mdash; Parkinson disease may present with stiffness in an older patient, but also with tremor and rigidity, including cogwheel rigidity, on examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"       \"Diagnosis of Parkinson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hyperparathyroidism",
"      </strong>",
"      &mdash; Hyperparathyroidism may present with proximal stiffness and aching, often in older patients, but with elevated parathyroid hormone and often with hypercalcemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Drug-induced myalgias or myositis",
"      </strong>",
"      &mdash; Symptoms of myalgias and aching may be due to the use of statins, but such patients usually do not exhibit signs of inflammation, and symptoms may be associated with elevated creatine kinase levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Depression",
"      </strong>",
"      &mdash; Depression may be associated with somatic symptoms and weight loss, and can occur in some patients with PMR. Patients with depression do not have typical proximal aching and morning stiffness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42369?source=see_link\">",
"       \"Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/54/42852?source=see_link\">",
"       \"Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized clinically by aching and morning stiffness in the shoulders, hip girdle, neck, and torso. It can be associated with giant cell (temporal) arteritis (GCA). Polymyalgia rheumatica (PMR) is almost exclusively a disease of adults over the age of 50 and the incidence increases progressively with advancing age. The average age at diagnosis is over 70 years. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination may reveal decreased range of motion of the shoulders, neck, and hips. Muscle tenderness is not prominent, and muscle strength is usually normal when carefully tested. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic laboratory finding is an elevation in the erythrocyte sedimentation rate (ESR) that can exceed 100",
"      <span class=\"nowrap\">",
"       mm/h,",
"      </span>",
"      although values below 40",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      are seen in a minority of patients. Elevated serum CRP may be more sensitive than a high ESR for the diagnosis of",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      monitoring relapses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PMR can be made in patients with the following features, in whom another disease to explain the findings is not present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age 50 years or older at onset of symptoms",
"     </li>",
"     <li>",
"      Bilateral aching and morning stiffness (lasting 30 minutes or more) persisting for at least one month, and involving at least two of the following three areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR) increased to 40",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      or more, or an increased C reactive protein in patients with a normal ESR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts add a prompt response of symptoms to glucocorticoids as an additional criterion. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diagnosis of PMR'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporal artery biopsy is NOT required in the absence of signs or symptoms of GCA. Evaluation including biopsy should be performed if symptoms of GCA develop, even if patients are on glucocorticoids. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation for GCA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of PMR includes early seronegative rheumatoid arthritis and a variety of other disorders that can usually be distinguished clinically from PMR. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/1\">",
"      Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/2\">",
"      Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch Intern Med 1997; 157:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/3\">",
"      Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/4\">",
"      Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/5\">",
"      Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/6\">",
"      Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003; 49:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/7\">",
"      Bernatsky S, Joseph L, Pineau CA, et al. Polymyalgia rheumatica prevalence in a population-based sample. Arthritis Rheum 2009; 61:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/8\">",
"      Weyand CM, Hunder NN, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994; 37:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/9\">",
"      Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/10\">",
"      Salvarani C, Cantini F, Olivieri I, Hunder GS. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol 1999; 26:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/11\">",
"      Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/12\">",
"      Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996; 35:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/13\">",
"      Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases. Arthritis Rheum 1996; 39:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/14\">",
"      Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996; 39:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/15\">",
"      Gonz&aacute;lez-Gay MA, Rodr&iacute;guez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997; 157:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/16\">",
"      Proven A, Gabriel SE, O'Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/17\">",
"      Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/18\">",
"      Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/19\">",
"      Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997; 127:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/20\">",
"      Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001; 28:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/21\">",
"      Moosig F, Czech N, Mehl C, et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 2004; 63:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/22\">",
"      Michet CJ, Matteson EL. Polymyalgia rheumatica. BMJ 2008; 336:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/23\">",
"      Rodriguez-Valverde V, Sarabia JM, Gonz&aacute;lez-Gay MA, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 1997; 102:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/24\">",
"      Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/25\">",
"      Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992; 19:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/26\">",
"      Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford) 2009; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/27\">",
"      Cutolo M, Cimmino MA, Sulli A. Polymyalgia rheumatica vs late-onset rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/28\">",
"      Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol 1999; 26:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/29\">",
"      Schaeverbeke T, Fatout E, Marc&eacute; S, et al. Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome? Ann Rheum Dis 1995; 54:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/30\">",
"      Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol 2000; 18:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/31\">",
"      Olivieri I, Garcia-Porrua C, Padula A, et al. Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatol Int 2007; 27:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/32\">",
"      Olivieri I, Salvarani C, Cantini F. Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? J Rheumatol 1997; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/33\">",
"      Pego-Reigosa JM, Rodriguez-Rodriguez M, Hurtado-Hernandez Z, et al. Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis Rheum 2005; 53:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/34\">",
"      Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1993; 20:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/35\">",
"      Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy. Arch Intern Med 1993; 153:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13832/abstract/36\">",
"      Little MA, Nazar L, Farrington K. Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis? QJM 2004; 97:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8235 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-211.167.112.14-DDD85A9494-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13832=[""].join("\n");
var outline_f13_32_13832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - MRI and ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - PET scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis of PMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Evaluation for GCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8166?source=related_link\">",
"      Pathogenesis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/54/42852?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42369?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40598?source=related_link\">",
"      Treatment of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13833="Methotrexate: Pediatric drug information";
var content_f13_32_13833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methotrexate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"    see \"Methotrexate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"    see \"Methotrexate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rheumatrex&reg;;",
"     </li>",
"     <li>",
"      Trexall&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methotrexate&reg;;",
"     </li>",
"     <li>",
"      ratio-Methotrexate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antirheumatic, Disease Modifying",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"      see \"Methotrexate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatomyositis: Oral: 15-20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week as a single dose once weekly or 0.3-1 mg/kg/dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     JIA: Oral, I.M., SubQ: Initial: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly; dosing may be increased to 15-20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week as a single dose or in 3 divided doses given 12 hours apart;",
"     <b>",
"      Note:",
"     </b>",
"     Subcutaneous administration is recommended with doses &gt;10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     since oral absorption decreases with higher doses; folic acid 1 mg daily or leucovorin calcium &le;5 mg weekly are often used to prevent folate depletion from methotrexate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antineoplastic dosage range:",
"     <b>",
"      Note:",
"     </b>",
"     Doses between 100-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      may require",
"     </b>",
"     leucovorin calcium rescue. Doses &gt;500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <b>",
"      require",
"     </b>",
"     leucovorin calcium rescue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, I.M.: 7.5-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week or every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 10 mg to 33,000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus dosing or continuous infusion over 6-42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Antineoplastic dosing schedules (adapted from Dorr RT and Von Hoff DD,",
"     <i>",
"      Cancer Chemotherapy Handbook",
"     </i>",
"     , 2nd ed, 1994): See table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Methotrexate Dosing Schedules",
"     </caption>",
"     <col align=\"left\" width=\"145\">",
"     </col>",
"     <col align=\"center\" width=\"165\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"110\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Route",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Frequency",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         *Followed with leucovorin rescue.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Conventional dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-20 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Twice weekly",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral, I.V.",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weekly",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15 mg/day for 5 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral, I.M.",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 2-3 weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Intermediate dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. push",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 2-3 weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         *",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. infusion",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 4-7 days",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-1 g/m",
"         <sup>",
"          2",
"         </sup>",
"         *",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. infusion",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 2-3 weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         High dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-12 g/m",
"         <sup>",
"          2",
"         </sup>",
"         *",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.V. infusion",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 1-3 weeks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pediatric solid tumors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;12 years: 12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     (dosage range: 12-18 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: 8 g/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 18 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Meningeal leukemia: I.T.: 6-12 mg/dose (maximum: 15 mg) based on age:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1 year: 6 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 year: 8 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 years: 10 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;3 years: 12 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.T. doses are administered at 2- to 5-day intervals until CSF counts return to normal followed by a dose once weekly for 2 weeks then monthly thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ALL (high-dose): I.V.: Loading dose: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     followed by a 24-hour infusion of 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ANLL: I.V.: 7.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-5 of treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Resistant ANLL: I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on day 1 of treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Non-Hodgkin's lymphoma: I.V.: 200-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; repeat every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Induction of remission in acute lymphoblastic leukemias: Oral: 3.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Remission maintenance: Oral, I.M.: 20-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     2 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trophoblastic neoplasms: Oral, I.M.: 15-30 mg/day for 5 days, repeat in 7 days for 3-5 courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head and neck cancer: Oral, I.M., I.V.: 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Meningeal leukemia: I.T.: Usual dose: 12 mg/dose (maximum dose: 15 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis:",
"     <b>",
"      Note:",
"     </b>",
"     Some experts recommend concomitant folic acid at a dose of at least 5 mg/week (except the day of methotrexate) to reduce hematologic, gastrointestinal, and hepatic adverse events related to methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 7.5 mg once weekly",
"     <b>",
"      or",
"     </b>",
"     2.5 mg every 12 hours for 3 doses/week; dosage exceeding 20 mg/week may cause a higher incidence and severity of adverse events; alternative dose: 10-15 mg once weekly; increase by 5 mg every 4 weeks to highest tolerated dose (maximum: 30 mg/week ) (Visser, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: 15 mg once weekly (dosage varies, similar to oral) (Braun, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Psoriasis:",
"     <b>",
"      Note:",
"     </b>",
"     Some experts recommend concomitant folic acid 1-5 mg/day (except the day of methotrexate) to reduce hematologic, gastrointestinal, and hepatic adverse events related to methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2.5-5 mg/dose every 12 hours for 3 doses given weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, I.M., SubQ: 10-25 mg given once weekly; titrate to lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     An initial test dose of 2.5-5 mg is recommended in patients with risk factors for hematologic toxicity or renal impairment (Kalb, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     61-80 mL/minute: Decrease dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     51-60 mL/minute: Decrease dose by 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Decrease dose by 50% to 70%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 25 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25 mg/mL (2 mL, 4 mL, 8 mL, 10 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trexall&trade;: 5 mg, 7.5 mg, 10 mg, 15 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatrex&reg;: 2.5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methotrexate may be administered I.V. push, I.V. intermittent infusion, or I.V. continuous infusion at a concentration &lt;25 mg/mL; doses &gt;100-300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     are usually administered by I.V. continuous infusion and are followed by a course of leucovorin calcium rescue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For intrathecal use, mix methotrexate without preservatives with NS, Elliotts B solution, or LR to a concentration not greater than 2 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, asparaginase, aztreonam, bleomycin, cefepime, ceftriaxone, cimetidine, cisplatin, cyclophosphamide, cytarabine, daunorubicin HCl, diphenhydramine, doripenem, doxorubicin HCl, doxorubicin liposome, etoposide, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, leucovorin calcium, linezolid, lorazepam, melphalan, mesna, methylprednisolone sodium succinate, metoclopramide, mitomycin, morphine, ondansetron, oxacillin, oxaliplatin, paclitaxel, piperacillin/tazobactam, prochlorperazine edisylate, ranitidine, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Chlorpromazine, gemcitabine, idarubicin, ifosfamide, midazolam, nalbuphine, promethazine, propofol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, droperidol, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, cytarabine, doxapram, doxorubicin HCl, fluorouracil, furosemide, heparin sodium, hydrocortisone sodium succinate, leucovorin calcium, mitomycin, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Droperidol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Metoclopramide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets and intact vials at room temperature (15&deg;C to 25&deg;C). Protect from light. Solution diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS is stable for 24 hours at room temperature (21&deg;C to 25&deg;C). Reconstituted solutions with a preservative may be stored under refrigeration for up to 3 months, and up to 4 weeks at room temperature. Intrathecal dilutions are stable at room temperature for 7 days, but it is generally recommended that they be used within 4-8 hours. Injection is incompatible with chlorpromazine, gemcitabine, ifosfamide, midazolam, promethazine, and propofol",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intrathecal mediations should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole), acute lymphocytic leukemias, meningeal leukemia, osteosarcoma, breast cancer, head and neck cancer (epidermoid), cutaneous T-Cell lymphoma (advanced mycosis fungoides), lung cancer (squamous cell and small cell), advanced non-Hodgkin's lymphoma [FDA approved in pediatrics (age not specified) and adults]; children with severe polyarticular juvenile idiopathic arthritis (JIA) who have failed to respond to other agents (FDA approved in ages 2-16 years); psoriasis (severe, recalcitrant, disabling), severe rheumatoid arthritis (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Has also been used for the treatment and maintenance of remission in Crohn's disease; ectopic pregnancy; dermatomyositis; bladder cancer, central nervous system tumors (including nonleukemic meningeal cancers), acute promyelocytic leukemia (maintenance treatment), soft tissue sarcoma (desmoid tumors)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methotrexate may be confused with mercaptopurine, methylPREDNISolone sodium succinate, metolazone, metroNIDAZOLE, mitoXANtrone, PRALAtrexate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Errors have occurred (resulting in death) when methotrexate was administered as &ldquo;daily&rdquo; dose instead of the recommended &ldquo;weekly&rdquo; dose.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MTX is an error-prone abbreviation (mistaken as mitoxantrone)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Trexall [U.S.] may be confused with Trexol brand name for tamadol [Mexico]; Truxal brand name for chlorprothixene [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions vary by route and dosage. Hematologic and/or gastrointestinal toxicities may be common at dosages used in chemotherapy; these reactions are much less frequent when used at typical dosages for rheumatic diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system (with intrathecal administration or very high-dose therapy):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arachnoiditis: Acute reaction manifested as severe headache, nuchal rigidity, vomiting, and fever; may be alleviated by reducing the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Subacute toxicity: Patients treated with 12-15 mg of intrathecal methotrexate may develop this in the second or third week of therapy; consists of motor paralysis of extremities, cranial nerve palsy, seizure, or coma. This has also been seen in pediatric cases receiving very high-dose I.V. methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Demyelinating encephalopathy: Seen months or years after receiving methotrexate; usually in association with cranial irradiation or other systemic chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, depigmentation or hyperpigmentation of skin, dermatitis, photosensitivity, pruritus, rash, reddening of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Diabetes, hyperuricemia, oligospermia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, gingivitis, glossitis, intestinal perforation, mucositis (dose dependent; appears in 3-7 days after therapy, resolving within 2 weeks), nausea, ulcerative stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemorrhage, leukopenia, myelosuppression (nadir: 7-10 days), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cirrhosis (chronic therapy), liver function tests increased (chronic therapy), portal fibrosis (chronic therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, nephropathy, renal failure; renal dysfunction: Manifested by an abrupt rise in serum creatinine and BUN and a fall in urine output; more common with high-dose methotrexate, and may be due to precipitation of the drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis; pneumonitis: Associated with cough, fever, and interstitial pulmonary infiltrates; treatment is to withhold methotrexate during the acute reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Immunosuppression, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute neurologic syndrome (at high dosages; symptoms include confusion, hemiparesis, transient blindness, and coma); acute respiratory distress syndrome, agranulocytosis, alveolitis, anaphylaxis, arrhythmia, arterial occlusion (acute), arterial thrombosis, cerebral thrombosis, cerebrovascular accident, chronic leukoencephalopathy, cognitive dysfunction (has been reported at low dosage), cryptococcosis, cytomegalovirus infection (including cytomegaloviral pneumonia, sepsis, nocardiosis), deep vein thrombosis, disseminated vaccinia (following smallpox immunization), dysarthria, enteritis, eosinophilia, erythema multiforme, exfoliative dermatitis, GI bleeding, gynecomastia, hepatic failure, hepatitis, herpes simplex, herpes zoster, histoplasmosis, hypogammaglobulinemia, hypotension, impotence, infertility, intestinal perforation, leukoencephalopathy (especially following craniospinal irradiation or repeated high-dose therapy), lymphoma (may regress with discontinuation), lymphoproliferative disorders, mesenteric ischemia (acute), MI, myocardial ischemia, nasal septum perforation, neutropenia, nodulosis, osteoporosis, pancreatitis, pericardial effusion, osteonecrosis and soft tissue necrosis (with radiotherapy), pericarditis, plaque erosions (psoriasis),",
"     <i>",
"      Pneumocystis carinii",
"     </i>",
"     pneumonia, pneumonia, proteinuria, pulmonary embolism, pulmonary fibrosis, radiation recall dermatitis, respiratory failure, retinal vein thrombosis, reversible posterior leukoencephalopathy syndrome (RPLS), seizure (more frequent in pediatric patients with ALL), skin ulceration, Stevens-Johnson syndrome, stroke, supraventricular arrythmia, syncope, telangiectasia, thromboembolism, thrombophlebitis, toxic epidermal necrolysis, tumor lysis syndrome, upper respiratory tract infection, ventricular arrythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methotrexate or any component; nursing mothers",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindications for patients with psoriasis or rheumatoid arthritis: Pregnancy, alcoholism, alcoholic liver disease or other chronic liver disease, immunodeficiency syndrome (overt or laboratory evidence); pre-existing blood dyscrasias (eg, bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13389594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered under the supervision of a physician experienced in the use of antimetabolite therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Due to the possibility of severe toxic reactions, fully inform patient of the risks involved; do not use in women of childbearing age unless benefit outweighs risks; methotrexate has been reported to cause fetal death and/or congenital anomalies",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; women of childbearing potential should not be started on methotrexate until pregnancy is excluded; do not use in pregnant women for treatment of RA or psoriasis. Bone marrow suppression may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may result in anemia, aplastic anemia, pancytopenia, leukopenia, neutropenia, and/or thrombocytopenia. Use caution in patients with pre-existing bone marrow suppression. Discontinue therapy in RA or psoriasis if a significant decrease in hematologic components is noted; immune suppression may lead to potentially fatal opportunistic infections",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use of low-dose methotrexate has been associated with the development of malignant lymphomas",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may regress upon discontinuation of therapy; treat lymphoma appropriately if regression is not induced by cessation of methotrexate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Methotrexate has been associated with acute (elevated transaminases) and potentially fatal chronic (fibrosis, cirrhosis) hepatotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Risk is related to cumulative dose (total dose: &ge;1.5 g)  and prolonged exposure (duration: &ge;2 years). Monitor closely (with liver function tests, including serum albumin) for liver toxicities. Liver enzyme elevations may be noted, but may not be predictive of hepatic disease in long-term treatment for psoriasis [but generally is predictive in rheumatoid arthritis (RA) treatment]. With long-term use, liver biopsy may show histologic changes, fibrosis, or cirrhosis; periodic liver biopsy is recommended with long-term use for psoriasis in patients with risk factors for hepatotoxicity, in patients with persistent abnormal liver function tests, and in RA patients; discontinue methotrexate with moderate-to-severe change in liver biopsy. Risk factors for hepatotoxicity include history of above moderate alcohol consumption, persistent abnormal liver chemistries, history of chronic liver disease (including hepatitis B or C), family history of inheritable liver disease, diabetes, obesity, hyperlipidemia, lack of folate supplementation during methotrexate therapy, and history of significant exposure to hepatotoxic drugs. Use caution with pre-existing liver impairment; may require dosage reduction. Use caution when used with other hepatotoxic agents (azathioprine, retinoids, sulfasalazine). May cause renal damage leading to acute renal failure, especially with high-dose methotrexate; monitor renal function and methotrexate concentrations closely, maintain adequate hydration and urinary alkalinization. Use caution in osteosarcoma patients treated with high-dose methotrexate in combination with nephrotoxic chemotherapy (eg, cisplatin). Methotrexate elimination is reduced in patients with renal impairment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Elimination is reduced in patients with ascites and/or pleural fluid",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may require dose reduction or discontinuation. Monitor closely for toxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause potentially life-threatening pneumonitis (may occur at any time during therapy and at any dosage)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor closely for pulmonary symptoms, particularly dry, nonproductive cough. Other potential symptoms include fever, dyspnea, hypoxemia, or pulmonary infiltrate. Neurotoxicity manifested as generalized or focal seizures has been reported in pediatric patients with acute lymphoblastic leukemia treated with I.V. methotrexate (1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Symptomatic patients were commonly noted to have leukoencephalopathy and/or microangiopathic calcifications. An acute, neurologic syndrome (confusion, hemiparesis, transient blindness, seizures, coma) has been reported in patients receiving high-dose methotrexate. Any dose level or route of administration may cause severe and potentially fatal dermatologic reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis, and erythema multiforme",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Radiation dermatitis and sunburn may be precipitated by methotrexate administration. Psoriatic lesions may be worsened by concomitant exposure to ultraviolet radiation. Tumor lysis syndrome may occur in patients with high tumor burden",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use appropriate prevention and treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Concurrent administration with NSAIDs may cause severe bone marrow suppression, aplastic anemia, and GI toxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Do not administer NSAIDs prior to or during high-dose methotrexate therapy; may increase and prolong serum methotrexate concentrations. Doses used for psoriasis may still lead to unexpected toxicities; use caution when administering NSAIDs or salicylates with lower doses of methotrexate for RA. Methotrexate may increase the concentrations and effects of mercaptopurine; may require dosage adjustments. Vitamins containing folate may decrease response to systemic methotrexate; folate deficiency may increase methotrexate toxicity. Concomitant methotrexate administration with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Diarrhea and ulcerative stomatitis may require interruption of therapy",
"     <b>",
"      [U.S. Boxed Warning",
"     </b>",
"     ]; death from hemorrhagic enteritis or intestinal perforation has been reported. Use with caution in patients with peptic ulcer disease, ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     When used for intrathecal administration, should not be prepared during the preparation of any other agents; after preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only; delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some injections contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of methotrexate products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites. Methotrexate formulations and/or diluents containing preservatives should not be used for intrathecal or high-dose therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein, SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Methotrexate may enhance the adverse/toxic effect of Leflunomide. Particular concerns are an increased risk of pancytopenia and/or hepatotoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Methotrexate may diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate.  Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: May enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Methotrexate. Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: Methotrexate may decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SulfaSALAzine: May enhance the hepatotoxic effect of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Methotrexate may increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Methotrexate may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milk-rich foods may decrease methotrexate absorption; folate may decrease drug response; folate deficiency states may increase methotrexate toxicity",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (psoriasis, rheumatoid arthritis) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Methotrexate may cause fetal death and/or congenital abnormalities.",
"     </b>",
"     Studies in animals and pregnant women have shown evidence of fetal abnormalities; therefore, the manufacturer classifies methotrexate as pregnancy category X (for psoriasis or RA). A pattern of congenital malformations associated with maternal methotrexate use is referred to as the aminopterin/methotrexate syndrome. Features of the syndrome include CNS, skeletal, and cardiac abnormalities. Low birth weight and developmental delay have also been reported. The use of methotrexate may impair fertility and cause menstrual irregularities or oligospermia during treatment and following therapy. Methotrexate is approved for the treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole) and has been used for the medical management of ectopic pregnancy and the medical management of abortion.",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for the treatment of psoriasis or RA in pregnant women.",
"     </b>",
"     Pregnancy should be excluded prior to therapy in women of childbearing potential. Use for the treatment of neoplastic diseases only when the potential benefit to the mother outweighs the possible risk to the fetus. Pregnancy should be avoided for &ge;3 months following treatment in male patients and &ge;1 ovulatory cycle in female patients. A registry is available for pregnant women exposed to autoimmune medications including methotrexate. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, creatinine clearance, serum creatinine, BUN, hepatic function tests, serum electrolytes, urinalysis, plasma methotrexate concentrations (see Leucovorin calcium rescue graph to evaluate plasma methotrexate concentration versus leucovorin calcium rescue dose); periodic liver biopsy for psoriatic patients with risk factors for hepatotoxicity receiving long-term treatment; patients with persistent abnormal liver function tests and RA patients; chest x-ray; pulmonary function tests if methotrexate-induced lung disease is suspected",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1048586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentrations &gt;1 x 10",
"     <sup>",
"      -7",
"     </sup>",
"     mol/L for more than 40 hours are toxic",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An antimetabolite that binds to dihydrofolate reductase blocking the reduction of dihydrofolate to tetrahydrofolic acid; depletion of tetrahydrofolic acid leads to depletion of DNA precursors and inhibition of DNA and purine synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1048590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Approximate time to benefit in treatment of rheumatoid arthritis: 3-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Average: 30%; variable absorption at low doses (&lt;30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ); incomplete absorption after large doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Completely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Small amounts excreted into breast milk; crosses the placenta; does not achieve therapeutic concentrations in the CSF; distributes to gallbladder, spleen, and skin; sustained concentrations are retained in the kidney and liver; V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.4-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to 7-hydroxymethotrexate; polyglutamates are produced intracellularly (active metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parenteral: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (terminal): Low dose &lt;30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : 3-10 hours; high dose: 8-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Small amounts in feces; primarily excreted unchanged in urine (90%) via glomerular filtration and active secretion by the renal tubule; 1% to 11% of a dose is excreted as the 7-hydroxy metabolite",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"      see \"Methotrexate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report to physician any fever, sore throat, black or tarry stools, yellowing of skin or eyes, bleeding or bruising, shortness of breath, painful urination; avoid alcohol. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Pregnancy should be avoided if either partner is receiving methotrexate; effective contraceptive measures must be used; avoid pregnancy for a minimum of 3 months after completion of therapy in male patients and for at least one ovulatory cycle in female patients.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Mild",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Methotrexate overexposure: The investigational rescue agent, glucarpidase, is an enzyme which rapidly hydrolyzes extracellular methotrexate into inactive metabolites, resulting in a rapid reduction of methotrexate concentrations. Glucarpidase is available for intrathecal (I.T.) use through an Emergency Use IND and for I.V. use under an Open-Label Treatment protocol.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barnhart KT, \"Clinical Practice. Ectopic Pregnancy,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(4):379-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/19625718/pubmed\" id=\"19625718\" target=\"_blank\">",
"        19625718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell EA, \"Pharmacotherapy of Juvenile Idiopathic Arthritis,&rdquo;",
"      <i>",
"       J Pharmacy Practice",
"      </i>",
"      , 2009, 22(1):17-28.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benz C, Tillis T, Tattelman E, et al, \"Optimal Schedule of Methotrexate and 5-Fluorouracil in Human Breast Cancer,\"",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1982, 42(5):2081-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/6175406/pubmed\" id=\"6175406\" target=\"_blank\">",
"        6175406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleyer AW, &ldquo;Clinical Pharmacology of Intrathecal Methotrexate II. An Approved Dosage Regimen Derived From Age-Related Pharmacokinetics,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1977, 61(8):1419-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/579164/pubmed\" id=\"579164\" target=\"_blank\">",
"        579164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braun J, K&auml;stner P, Flaxenberg P, et al, \"Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis: Results of a Six-Month, Multicenter, Randomized, Double-Blind, Controlled, Phase IV Trial,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(1):73-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/18163521/pubmed\" id=\"18163521\" target=\"_blank\">",
"        18163521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crom WR, Glynn-Barnhart AM, Rodman JH, et al, &ldquo;Pharmacokinetics of Anticancer Drugs in Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1987, 12(3):168-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/3555940/pubmed\" id=\"3555940\" target=\"_blank\">",
"        3555940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH, Brewer EJ, Kuzmina N, et al, &ldquo;Methotrexate in Resistant Juvenile Rheumatoid Arthritis. Results of the USA-USSR Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(16):1043-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/1549149/pubmed\" id=\"1549149\" target=\"_blank\">",
"        1549149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glantz MJ, Cole BF, Recht L, et al, \"High-Dose Intravenous Methotrexate for Patients With Nonleukemic Leptomeningeal Cancer: Is Intrathecal Chemotherapy Necessary?\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(4):1561-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/9552066/pubmed\" id=\"9552066\" target=\"_blank\">",
"        9552066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glantz MJ, Jaeckle KA, Chamberlain MC, et al, \"A Randomized Controlled Trial Comparing Intrathecal Sustained-Release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients With Neoplastic Meningitis From Solid Tumors,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 1999, 5(11):3394-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/10589750/pubmed\" id=\"10589750\" target=\"_blank\">",
"        10589750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greaves MW and Weinstein GD, &ldquo;Treatment of Psoriasis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(9):581-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/7838193 /pubmed\" id=\"7838193 \" target=\"_blank\">",
"        7838193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Atandards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalb RE, Strober B, Weinstein G, et al, \"Methotrexate and Psoriasis: 2009 National Psoriasis Foundation Consensus Conference,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2009, 60(5):824-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/19389524/pubmed\" id=\"19389524\" target=\"_blank\">",
"        19389524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network (NCCN)&reg;, \"Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,\" Version 2.2009. Available at: file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz S, Borner K, M&uuml;ller K, et al, \"Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients With Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy,\"",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2007, 12(11):1299-308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/18055849/pubmed\" id=\"18055849\" target=\"_blank\">",
"        18055849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose CD, Singsen BH, and Eichenfield AH, &ldquo;Safety and Efficacy of Methotrexate Therapy for Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 117(4):653-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/2213397 /pubmed\" id=\"2213397 \" target=\"_blank\">",
"        2213397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Visser K, Katchamart W, Loza E, et al, \"Multinational Evidence-Based Recommendations for the Use of Methotrexate in Rheumatic Disorders With a Focus on Rheumatoid Arthritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists in the 3E Initiative,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2009, 68(7):1086-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/19033291/pubmed\" id=\"19033291\" target=\"_blank\">",
"        19033291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Murphy RF, et al, \"Carboxypeptidase-G2, Thymidine, and Leucovorin Rescue in Cancer Patients With Methotrexate-Induced Renal Dysfunction,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(5):2125-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/9164227/pubmed\" id=\"9164227\" target=\"_blank\">",
"        9164227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC, Balis FM, Shalabi A, et al, \"Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2,\"",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(20):1557-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/32/13833/abstract-text/15494606/pubmed\" id=\"15494606\" target=\"_blank\">",
"        15494606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12595 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13833=[""].join("\n");
var outline_f13_32_13833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709040\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194555\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194556\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048583\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048575\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194526\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194511\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048588\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194608\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048578\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048587\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194611\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194607\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048592\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389594\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048573\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837690\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194520\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048595\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194522\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194538\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048582\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048586\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048572\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048590\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048591\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048580\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048593\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=related_link\">",
"      Methotrexate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=related_link\">",
"      Methotrexate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13834="Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques";
var content_f13_32_13834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Michael T Jaklitsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Carlos M Mery, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Bryan M Burt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13834/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/32/13834/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/32/13834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung metastases from a primary extrapulmonary malignancy are often a manifestation of widespread dissemination; however, some patients have no other evidence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/1\">",
"     1",
"    </a>",
"    ]. Extensive experience with pulmonary metastasectomy in a number of different cancers has confirmed that resection can substantially prolong survival and cure some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/2\">",
"     2",
"    </a>",
"    ]. Based upon these observations, aggressive resection of isolated pulmonary metastases has become a widely accepted treatment for appropriately selected patients.",
"   </p>",
"   <p>",
"    The benefits of metastasectomy, selection criteria, preoperative evaluation, and techniques for surgical resection are discussed here. Outcomes according to histology are discussed elsewhere, as are issues specific to resection of soft tissue sarcoma lung metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .) The integration of surgery into multidisciplinary therapy for patients with specific malignancies is discussed in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of pulmonary metastases are asymptomatic. Most are detected incidentally during the initial staging workup of a primary cancer, or from routine post treatment surveillance radiographic studies, typically chest computed tomography (CT). Symptoms of cough, pain, or hemoptysis may be present in patients with hilar involvement, particularly when the metastases abut or invade the bronchi. Rarely, patients with peripheral metastases present with a spontaneous pneumothorax due to tumor disruption of the visceral pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BENEFITS OF RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials evaluating the benefit of resection in patients with pulmonary metastases. However, multiple case reports and small series suggest that resection prolongs survival and cure was possible in some patients with isolated lung involvement. The following retrospective reviews illustrate the benefits of a complete pulmonary metastasectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A review from the International Registry of Lung Metastases identified 5206 patients with a variety of primary metastatic tumors (carcinomas, sarcomas, germ cell tumors, and melanomas) who underwent a pulmonary metastasectomy; this series included 4572 (88 percent) in whom complete resection was carried out. [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"       4",
"      </a>",
"      ]. The overall 5, 10, and 15 year survival rates were 36, 26, and 22 percent, respectively. Factors associated with a better prognosis included germ cell etiology, disease free interval of 36 months, and a single metastatic lesion.",
"     </li>",
"     <li>",
"      A retrospective review of 178 consecutive patients undergoing 256 surgical resections for pulmonary metastasis identified a complete resection in 248 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/5\">",
"       5",
"      </a>",
"      ]. The five year survival based upon primary disease site and complete resection was the highest for patients with renal cell carcinomas (51.4 percent), followed by colon or rectal cancer (50.3 percent), sarcoma (21.7 percent), and melanoma (25 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with pulmonary metastasectomy requires a multidisciplinary approach that includes both the medical oncologist and the thoracic surgeon. The goal is to restrict surgery to those patients who are most likely to benefit, either in terms of prolonging survival or symptom palliation, and to optimize the timing of surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Criteria for resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no published guidelines from expert groups (with the exception of guidelines for resectability of colorectal cancer lung metastases from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/6\">",
"     6",
"    </a>",
"    ]), most clinicians would accept the following criteria for pulmonary metastasectomy. For patients who do not meet these criteria, stereotactic radiotherapy, and radiofrequency ablation or cryoablation, offer a local treatment alternative to resection for local control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17143?source=see_link\">",
"     \"Stereotactic body radiation therapy for primary and metastatic lung tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"     \"Radiofrequency ablation of lung tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20900?source=see_link\">",
"     \"Cryoablation of lung tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Criteria for resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pulmonary metastases appear to be completely resectable based upon preoperative imaging (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Computed tomography'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Adequate cardiopulmonary reserve to undergo resection",
"     </li>",
"     <li>",
"      Technical feasibility of the operation",
"     </li>",
"     <li>",
"      Controlled primary tumor site",
"     </li>",
"     <li>",
"      Absence of extrapulmonary metastatic disease; if present, the disease must be controllable with surgery or another treatment modality. We generally recommend a fluorodeoxyglucose (FDG)-PET scan prior to pulmonary metastasectomy to optimize the selection of candidates for resection. All extrathoracic areas of suspicious FDG uptake should be vigorously investigated prior to surgery, and surgery in the chest should not be done unless all known deposits of disease are being treated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preoperative evaluation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Resection of one or more lung lesions may also be indicated in a patient with a known malignancy when:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A new primary lung cancer cannot be excluded",
"     </li>",
"     <li>",
"      Symptomatic metastases (eg, bronchial obstruction with distal suppuration) cannot be managed in any other way",
"     </li>",
"     <li>",
"      Tissue needs to be obtained for a novel therapeutic strategy (eg, an autologous vaccine), and preferably within the confines of a clinical trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognostic determinants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors influence survival following metastasectomy. The presence of one or more of poor prognostic factors does not constitute an absolute contraindication to metastasectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/11\">",
"     11",
"    </a>",
"    ]. Unfavorable prognostic factors include an inability to completely resect all metastatic disease, a short disease-free interval following treatment of the primary tumor, a large number of pulmonary metastases, and involved lymph nodes. Tumor histology also influences outcomes. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Lymphadenectomy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Completeness of resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all reports indicate that complete resection of metastatic disease is associated with more favorable outcomes. In the International Registry series, for example, the median survival with complete versus incomplete resection was 35 versus 15 months, and the five-year survival rate was 36 versus 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Disease-free interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early series yielded conflicting results about the importance of disease-free interval on outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/12\">",
"     12",
"    </a>",
"    ], data from the International Registry indicate higher five-year survival rates for patients with a disease-free interval of greater than 36 months (45 versus 33 percent for a disease-free interval of less than one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Number of lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the International Registry indicate better five-year survival for patients with a single metastatic focus (single focus 43 percent versus 34 and 27 percent for those with two to three, or greater than three metastases, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"     4",
"    </a>",
"    ]. This observation holds true both for patients with sarcomas and epithelial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inverse relationship between the number of metastases and survival is likely due to multiple factors. The higher the number of pulmonary metastases, the greater the probability of incomplete resection (",
"    <a class=\"graphic graphic_figure graphicRef70943 \" href=\"UTD.htm?19/41/20126\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/12\">",
"     12",
"    </a>",
"    ], the likely heavier burden of occult disease diffusely in the lung, and the greater the probability of disease recurrence in the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/14\">",
"     14",
"    </a>",
"    ]. Additionally, if several nodules need to be removed from the same lobe or a central nodule needs to be removed, a lobectomy may be required rather than wedge resection. As more lung tissue is removed, perioperative risk increases.",
"   </p>",
"   <p>",
"    For patients with multiple metastases, there is no consensus among thoracic surgeons as to what disease burden represents an insurmountable obstacle. The important issue is the feasibility of resecting all sites of disease, not the number of metastases per se, although the two are related. In a series of 92 patients undergoing pulmonary metastasectomy for renal cell cancer, the chance of a complete resection was over 80 percent for patients with three or fewer nodules identified on preoperative CT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, if there were more than six nodules on the CT, the chance of a complete resection was no more than 20 percent.",
"   </p>",
"   <p>",
"    If resection is not feasible at the time of exploration (eg, for technical considerations such as an incomplete pulmonary fissure or proximity to a major vascular structure that was inapparent on the preoperative radiographs), intraoperative ablation using either cryotherapy or radiofrequency ablation (RFA) could be considered. Another alternative is the placement of fiducials for postoperative irradiation. Where available, techniques such as frameless stereotactic radiosurgery provide an opportunity to treat focal areas of the lung to high radiation doses, while preserving adjacent normal tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lymph node spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary metastases may be accompanied by hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal lymph node involvement; it is believed (but not proven) that this nodal disease arises from spread through the pulmonary lymphatics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/15\">",
"     15",
"    </a>",
"    ]. The frequency of lymphatic involvement in patients with pulmonary metastases has not been fully characterized, in part because a systematic lymph node dissection has not been considered a standard approach in this setting. In retrospective reviews, unsuspected metastatic disease in hilar or mediastinal lymph nodes was revealed in 5 to 33 percent of cases, depending on histology (lymph node metastases are more common in patients with carcinoma than sarcoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4,16-22\">",
"     4,16-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymph node involvement is an important negative prognostic factor in patients undergoing metastasectomy, regardless of histology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/13,17,18,21,23-26\">",
"     13,17,18,21,23-26",
"    </a>",
"    ]. However, not all patients with pulmonary metastases and documented hilar or mediastinal nodal metastases are destined to recur, particularly if they have renal cell carcinoma and disease that is limited to the intrapulmonary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hilar nodes that is amenable to anatomic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/13,18,21,25\">",
"     13,18,21,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\", section on 'Renal cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 92 patients undergoing pulmonary metastasectomy for renal cell cancer, 32 had information available from intraparenchymal and mediastinal lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/13\">",
"       13",
"      </a>",
"      ]. Eighteen had involved N1 (intrapulmonary or hilar) nodes and 10 had N2 (ipsilateral mediastinal) nodes. The presence of nodal metastases (at any site) significantly worsened prognosis, but the estimated five-year survival of patients with three involved nodes was still about 30 percent (versus 66 percent with no nodes involved).",
"     </li>",
"     <li>",
"      In another series, 124 patients underwent 139 pulmonary metastasectomies with mediastinal node dissection or sampling [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/21\">",
"       21",
"      </a>",
"      ]. Lymph node involvement was confirmed in 25 (20 percent), 10 in N1 (intrapulmonary or hilar) nodes, and 15 in N2 (mediastinal) nodes. The estimated five-year survival after resection was 60 percent for subjects without nodal metastases and it was 17 and 0 percent for those with N1 and N2 disease, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data provide support for the view that surgical staging of the mediastinal and hilar lymph nodes prior to pulmonary metastasectomy provides diagnostic and prognostic information, as well as a potential therapeutic benefit. Whether the presence (and location) of documented nodal involvement should influence the decision to proceed with resecting the parenchymal metastases is controversial and discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Lymphadenectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate patient selection is key to successful surgical resection of pulmonary metastases. In addition to thoracic CT, several other studies and a diagnostic biopsy may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate preoperative assessment and operative planning are dependent upon cross-sectional imaging. Thin-section imaging of the chest using high-resolution helical CT is the preferred modality, detecting approximately 20 to 25 percent more nodules than conventional CT, and the reliable detection of nodules as small as 2 to 3 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, this improved sensitivity is at the expense of specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17080?source=see_link&amp;anchor=H3#H3\">",
"     \"Computed tomographic and positron emission tomographic scanning of pulmonary nodules\", section on 'Technical aspects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of pathologic mediastinal adenopathy on CT should prompt a biopsy via mediastinoscopy, or endobronchial ultrasound-guided fine needle aspiration cytology. Although technically possible, most consider histologic involvement of N2 (mediastinal) nodes to represent a contraindication to attempted resection. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Lymphadenectomy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"     \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new pulmonary lesion in a patient with a known malignancy may represent a metastasis, a second primary lung cancer (particularly if the patient is a smoker), or a benign lesion.",
"   </p>",
"   <p>",
"    There are no pathognomonic radiographic features that distinguish metastatic disease from a new primary lung cancer or from benign processes. Metastatic nodules are typically well-circumscribed, spherical deposits with smooth margins, and are predominantly subpleural or located in the outer third of the lung fields. In contrast, primary lung cancers are usual single, often have irregular borders and associated linear densities, and more often are located centrally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When multiple nodules are present, the probability of metastatic disease increases significantly. However, exceptions to this general rule include primary bronchioloalveolar carcinomas, which may present with multifocal pulmonary nodules, and ground glass opacification, which is often multifocal and may be seen with severe acute and chronic nonmalignant pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9946?source=see_link\">",
"     \"Bronchioloalveolar carcinoma, including adenocarcinoma in situ\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link&amp;anchor=H12#H12\">",
"     \"High resolution computed tomography of the lungs\", section on 'Ground glass opacification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A new solitary pulmonary nodule appearing in a patient with a prior cancer will be malignant in more than three-fourths of cases. In a series of 1104 cases undergoing resection at a single institution, among patients without a history of antecedent malignancy, 63 percent of resected solitary nodules were malignant, while in patients with a history of lung or extrapulmonary cancer approximately 80 percent were malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nodule size also influenced the likelihood that a lesion was malignant, and that it represented a primary lung cancer rather than a metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/30\">",
"     30",
"    </a>",
"    ]. For patients with a history of prior extrathoracic malignancy, the probability that a solitary pulmonary nodule was malignant ranged from 67 percent for nodules &le;1 cm in diameter to 91 percent for nodules &gt;3 cm. For lesions &le;3 cm, there was an equal likelihood that the nodule represented a primary lung cancer or a metastasis; lung cancer was more common than metastasis if the nodule was &gt;3 cm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although assessment of the clinical scenario and a lesion's radiographic characteristics by CT may provide clues as to whether an individual lesion is benign or malignant, it is not possible to reliably distinguish a metastasis from a primary lung cancer. Resection of the nodule is the most reliable method for establishing the diagnosis and is essential to design the most adequate therapeutic strategy to maximize survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Assessment of lesion stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;We delay open surgical intervention for six to eight weeks in order to evaluate the natural history of untreated disease through repeat CT scanning. Patients who rapidly develop extrapulmonary metastases may be spared the morbidity of unnecessary thoracic surgery. This also ensures that a small number of mature (eg, large and fairly uniform in size) target lesions have not evolved into innumerable lesions with a constellation of sizes, which may change the surgical approach. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Timing of surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical practice varies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/31\">",
"     31",
"    </a>",
"    ], we recommend a PET scan prior to metastasectomy to optimize patient selection for pulmonary metastasectomy. PET is not necessarily more sensitive than high-resolution CT for detection of pulmonary metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/32\">",
"     32",
"    </a>",
"    ]. Like CT, PET has limited sensitivity for lesions &lt;1 cm in size [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/33\">",
"     33",
"    </a>",
"    ], and sensitivity is not improved by integrated",
"    <span class=\"nowrap\">",
"     PET/CT.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    results of the PET scan also cannot be used reliably to classify CT-discovered thoracic lesions as benign or malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, a negative PET scan of the chest should not influence the decision to pursue resection. If enlarging lung nodules (particularly if they have the characteristic CT appearance of metastases), are present without other recognized deposits of disease, we still favor surgical resection if possible for both diagnostic and potentially therapeutic purposes, even if the PET scan is negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\", section on 'FDG-PET'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main value of PET is its high level of sensitivity for detecting extrathoracic disease. Metastasectomy should not be done unless all known disease deposits are being treated (except if the patient is enrolled in a protocol such as a vaccine trial, or for symptomatic lesions that cannot be treated by other means). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Criteria for resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In one of the only studies to specifically address the benefit of PET in this setting, 86 patients with proven or suspected lung metastases, deemed potentially resectable after conventional CT scan, underwent preoperative PET [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/35\">",
"     35",
"    </a>",
"    ]. In 19 cases (21 percent), lung surgery was excluded based on the PET results, due to the finding of extrapulmonary metastases (11 cases), an unexpected primary site recurrence (2 cases), mediastinal lymphadenopathy (2 cases), or benign disease (4 cases).",
"   </p>",
"   <p>",
"    The benefit of PET for patients with soft tissue sarcoma metastases (where extrathoracic metastases are rare) is less certain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive extrathoracic uptake on a PET scan is not sufficient evidence to exclude a patient from surgery for lung metastases. All suspicious extrathoracic areas should be vigorously investigated (usually with a diagnostic biopsy) prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Brain imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We routinely perform brain imaging prior to resection of apparently isolated pulmonary metastases for patients who have tumors that frequently metastasize to the brain (eg, breast cancer, melanoma). The presence of brain metastases are a contraindication to pulmonary resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Need for preoperative tissue diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultimately, the diagnosis of pulmonary metastases is made by tissue sampling. In patients with highly suspicious lesions that have a characteristic CT appearance (eg, round, peripheral, multiple), definitive tissue diagnosis is often made after surgical resection of the metastases. However, in many cases, preoperative CT-guided fine needle aspiration (FNA) biopsy is a useful means to obtain tissue less invasively, particularly if the diagnosis of metastatic disease is in question, the patient is a poor or borderline operative candidate, or has a primary tumor (eg, testicular germ cell tumor, lymphoma) for which surgery may not be necessary.",
"   </p>",
"   <p>",
"    Particularly for lesions less than 1 cm in size, video-assisted thoracoscopic surgery (VATS) may be useful to establish a diagnosis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'VATS procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy (with or without endobronchial ultrasound) is indicated as part of the evaluation in cases of centrally located lesions identified on CT, in patients with symptoms of airway involvement, and for cell types that are prone to endobronchial involvement such as breast, colon, and renal cell cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/36\">",
"     36",
"    </a>",
"    ]. Bronchoscopy is performed preoperatively when positive findings would contraindicate operative intervention. For patients who require general anesthesia, bronchoscopy is performed in the operating room as a component of a staging procedure prior to metastasectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of curative resection of pulmonary metastases is complete identification and removal of all foci of malignancy with preservation of a maximal amount of normal lung tissue. This goal is achieved first with staging procedures (bronchoscopy, mediastinoscopy) to assess the extent of parenchymal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal disease, followed traditionally with open thoracotomy, bimanual palpation of the lung(s), and resection of all identifiable disease.",
"   </p>",
"   <p>",
"    Minimally invasive approaches to thoracic surgery have become increasingly popular for resection of pulmonary metastases. Many standard thoracic operations, characterized in name by the amount of lung tissue removed (eg, wedge resection, segmentectomy, lobectomy, pneumonectomy) can be performed either by open thoracotomy or minimally invasive techniques.",
"   </p>",
"   <p>",
"    Minimally invasive thoracic surgical techniques can be described as \"thoracoscopic\" or \"video-assisted\". Thoracoscopic surgery involves multiple ports, but none larger than a fingerbreadth, while video assisted thoracoscopic surgery often incorporates a minithoracotomy incision no longer than the length of a finger (10 cm). Minimally invasive techniques are often collectively referred to as \"VATS\", video-assisted thoracoscopic surgery, although the literature is variable, and terminology is not standardized [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/37\">",
"     37",
"    </a>",
"    ]. We will use the term \"VATS\" to refer to techniques not utilizing standard thoracic incisions. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Open thoracotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Choice of technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to pursue a minimally invasive technique versus open thoracotomy depends upon characteristics of the metastases including their location, number, and size as well as lesion stability as judged on CT scan. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Computed tomography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, a wedge resection by VATS is most appropriate for stable, peripheral metastases, each of which is no greater than 3 cm in size. There should be a small number of nodules; a single metastasis is ideal. Numerous target lesions may preclude a VATS approach, although there is no consensus among thoracic surgical oncologists or sarcoma specialists as to what disease burden represents an insurmountable obstacle.",
"   </p>",
"   <p>",
"    A wedge resection requires a margin of 1 cm, which is easily accomplished when the metastasis is peripheral (eg, outer third of lung field as seen on chest CT). For more centrally located lesions, this margin cannot be achieved because excessive tissue tension prevents the closure of the remaining lung tissue.",
"   </p>",
"   <p>",
"    Central lesions are better approached with either segmentectomy or lobectomy, and open thoracotomy may be preferred, though lobectomy can also be performed in a minimally invasive manner (eg, VATS lobectomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with one or more pulmonary metastases are likely to develop additional pulmonary lesions over time. Following potentially curative metastasectomy, additional lesions are identified in 50 percent of cases due to the subsequent growth of previously undetectable lesions. Smaller lesions have a shorter doubling time and, therefore, a faster growth rate than larger lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/38\">",
"     38",
"    </a>",
"    ]. New lesions are recognized when these tumor deposits grow and become recognizable as different from surrounding lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delaying intervention after a pulmonary metastasis is first identified may allow initially occult metastases to become clinically apparent, permitting a more complete resection and better long-term outcomes. This was illustrated in a retrospective review of 68 patients who underwent pulmonary metastasectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/39\">",
"     39",
"    </a>",
"    ]. On multivariate analysis, the only independently significant prognostic factor for survival was longer interval (greater than three months) from detection of pulmonary metastases to resection.",
"   </p>",
"   <p>",
"    Timing for metastasectomy, however, depends upon the anticipated surgical approach (open versus minimally invasive). As an example, we frequently choose not to delay a VATS metastasectomy for an isolated peripheral nodule in a favorable location because recovery time and surgical risk are minimal, and recurrent disease is technically easier to resect with a repeat VATS approach because of fewer adhesions. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'VATS procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On the other hand, open thoracotomy as would be required for a deep nodule or numerous nodules of varying sizes, is associated with longer recovery and more morbidity. Allowing the full extent of disease to be revealed by delaying open surgery is beneficial to the patient. In this situation, we delay open surgical intervention for six to eight weeks in order to evaluate the natural history of untreated disease through repeat CT scanning. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Computed tomography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The finding of equivalent long-term survival rates for recurrent disease following VATS or open metastasectomy implies that there may be little clinical significance to nodules missed with initial VATS that are resected at a later date [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Intraoperative staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a pulmonary nodule in a patient with a previous history of malignancy includes primary bronchogenic carcinoma, metastatic disease to the lungs, or a benign lesion. We assess these patients with a standard workup that includes bronchoscopy (with or without endobronchial ultrasound) and mediastinoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/19,42\">",
"     19,42",
"    </a>",
"    ]. Intraoperative pulmonary palpation may also be performed as part of the overall staging. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above.) Most clinicians consider the presence of confirmed mediastinal (N2) nodal metastases to represent a contraindication to metastasectomy because of the poor long-term outcome (",
"    <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/11,25\">",
"     11,25",
"    </a>",
"    ]. In contrast, the presence of hilar or intrapulmonary nodal metastases is not necessarily a contraindication to metastasectomy (particularly for renal cell cancer) as long as anatomic resection is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/13,23,24\">",
"     13,23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Lymphadenectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoscopy is often performed preoperatively in patients with pulmonary symptoms or to obtain a tissue specimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"       \"Flexible bronchoscopy: Indications and contraindications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link\">",
"       \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H17\">",
"       'Need for preoperative tissue diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mediastinoscopy is performed through a horizontal incision one centimeter above the suprasternal notch to assess the presence of paratracheal mediastinal nodal metastases. Dissection is carried into the pretracheal space to the level of the carina to form a tunnel for the mediastinoscope, which is advanced to view the mediastinum. Suspicious lymph nodes are sampled and sent for frozen section analysis.",
"     </li>",
"     <li>",
"      Bimanual palpation of the lung parenchyma is a traditional component of intraoperative staging to optimize curative resection, especially when more than one lesion is identified preoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/7\">",
"       7",
"      </a>",
"      ]. Although helical CT is more sensitive than older CT techniques for detection of small pulmonary nodules, it still misses a substantial number of metastases compared to manual palpation (sensitivity relative to surgical palpation 60 to 80 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/29,43-45\">",
"       29,43-45",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Computed tomography'",
"      </a>",
"      above.) Bimanual palpation requires an open thoracotomy. However, palpation of the lung parenchyma is possible during VATS to a limited extent (fingertips through a \"minithoracotomy\" incision) or with adjunctive procedures, such as the use of a substernal hand port permitting palpation of the lung(s) with one hand [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Open thoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of pulmonary metastases by a thoracotomy incision uses single-lung anesthesia for complete atelectasis of the non-ventilated lung. Open thoracotomy exposes the chest cavity, facilitating bimanual palpation of the pulmonary parenchyma, and resection of visible and palpable metastases.",
"   </p>",
"   <p>",
"    Perioperative mortality rates of pulmonary metastasectomy do not differ from those of resection for lung cancer and vary between 0.6 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"     4",
"    </a>",
"    ]. The mortality of pulmonary surgery is related to the amount of lung tissue removed with mortality rates of 4 to 10 percent for pneumonectomy, and consistently less than 1 percent following wedge resection.",
"   </p>",
"   <p>",
"    A conservative approach, removing the least amount of lung tissue needed to render the patient free of disease, results in greater cardiopulmonary reserve to withstand subsequent treatments should there be a recurrence. Wedge resection is often sufficient for peripheral nodules but segmentectomy, lobectomy, or even pneumonectomy may be required for lesions at the hilum or in the central part of the lobe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Unilateral radiographic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the thoracotomy incision chosen depends on the location of the disease to be treated; anterior and posterolateral approaches are most common.",
"   </p>",
"   <p>",
"    A bilateral approach is indicated only in those patients who present radiographically with bilateral metastases. For patients who appear to have unilateral disease, inspection of both hemithoraces frequently identifies occult tumor deposits. However, bilateral exploration and resection has not produced a survival advantage compared to a unilateral approach [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/47\">",
"     47",
"    </a>",
"    ]. Further, recurrence in the ipsilateral lung was as common as recurrence in the contralateral lung in patients who underwent bilateral exploration with complete resection to treat unilateral disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Bilateral radiographic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known bilateral lesions can be managed with median sternotomy, bilateral anterior thoracotomy (clamshell incision), or a bilateral sequential thoracotomy (",
"    <a class=\"graphic graphic_table graphicRef54065 \" href=\"UTD.htm?33/53/34651\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sternotomy allows the simultaneous examination of both lungs and identification and treatment of contralateral occult disease. The main advantages of this approach are reduced postoperative pain and less impairment of pulmonary function (",
"      <a class=\"graphic graphic_table graphicRef54065 \" href=\"UTD.htm?33/53/34651\">",
"       table 1",
"      </a>",
"      ). Disadvantages include more difficult exposure of the costovertebral lung fields, and limited visualization of the left lower lobe because of the heart. The sternal approach may also not be feasible in a patient who has had a previous sternotomy (eg, heart bypass). Longitudinal sternal transection carries a risk of a sternal wound infection, however, the incidence is low. Sternal wound infection (as with any wound infection) can delay recovery and initiation of adjuvant therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H18#H18\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Sternal wound infection and mediastinitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clamshell incision (bilateral anterior thoracotomy) provides excellent exposure to the posterior aspect of both lungs, but is associated with the most postoperative pain. Because the sternum is divided horizontally, there is also a risk for sternal wound infection. However, because both the internal mammary arteries are divided, the risk may be greater (",
"      <a class=\"graphic graphic_table graphicRef54065 \" href=\"UTD.htm?33/53/34651\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H18#H18\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Sternal wound infection and mediastinitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bilateral sequential thoracotomy is a good approach when exposure of the posterior aspects of both lungs and systematic hilar lymph node dissection is needed. Lateral thoracotomy incisions can be painful and a recuperation interval of six weeks is typically required (",
"      <a class=\"graphic graphic_table graphicRef54065 \" href=\"UTD.htm?33/53/34651\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Role for extended resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic lesions extending beyond the lung and involving the diaphragm, chest wall, mediastinum, or pericardium are potentially resectable en bloc provided negative margins can be achieved. Five-year survival rates as high as 25 percent are reported following extended resections that include the chest wall and diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     VATS procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first series using video-assisted thoracoscopic surgery (VATS) to perform metastasectomy was reported in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/49\">",
"     49",
"    </a>",
"    ]. Thoracoscopy involves the passage of a videoscope through the chest wall giving the surgeon a \"window\" for direct visualization into the chest. Additional ports are placed through the chest wall to allow for various instruments. VATS is less invasive than open thoracotomy; however, like thoracotomy, must be performed in the operating room under general anesthesia with single lung ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"     \"An overview of medical thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of fewer and smaller incisions, VATS is associated with less pain, faster postoperative recovery, shortened hospital stay, and decreased long-term morbidity (",
"    <a class=\"graphic graphic_table graphicRef54065 \" href=\"UTD.htm?33/53/34651\">",
"     table 1",
"    </a>",
"    ). Intrathoracic postoperative adhesions are milder with VATS compared to open thoracotomy. VATS has the advantage of shortened recuperation time and decreased blood loss in patients who require repeat resection after recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VATS can be used to resect most metastatic lesions, as the majority are located in the peripheral one-third of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/51\">",
"     51",
"    </a>",
"    ]. Conversion from a VATS approach to an open thoracotomy is appropriate for lesions located more centrally.",
"   </p>",
"   <p>",
"    Because of a lack of bimanual palpation, there is a greater likelihood of leaving behind undetected foci of tumor with VATS as compared to open thoracotomy (35 percent with some tumors, such as a sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/52\">",
"     52",
"    </a>",
"    ]). However, intrathoracic recurrence rates of clinically significant disease are reported to be between 18 and 49 percent for VATS, similar to that reported with open thoracotomy (16 to 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/50\">",
"     50",
"    </a>",
"    ]. Some practitioners have adopted the use of a substernal hand port to address this shortcoming [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, VATS is associated with procedure-related recurrences at the pulmonary resection stump site (staple line), port site, and pleural surfaces. A margin of at least 1 cm is recommended to prevent staple line recurrence. As a general rule, the margin should be at least as large as the width as the maximal diameter of the nodule removed. To avoid intrathoracic and port site seeding, the resected specimen is placed intact into a sterile specimen bag and delivered through the port site. It is important to examine the cut surface of the resected specimen to confirm that the resection margin is free of tumor; frozen-section histologic analysis should be undertaken when indicated.",
"   </p>",
"   <p>",
"    As discussed above, there is no consensus regarding a preference for open thoracotomy over a VATS procedure. Some argue that thoracoscopic resection is a valid approach only for patients with a solitary pulmonary nodule on preoperative chest CT, where the risk of additional disease is small [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. On the other hand, proponents of VATS argue that while open surgical exploration identifies radiographically occult nodules, these can be resected with VATS in the future, once they become detectable on surveillance CT scans, without adversely affecting survival. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Repeat metastasectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no randomized trials comparing outcomes between open and thoracoscopic resection and few retrospective comparisons. Data suggest that patients do at least as well after VATS as after thoracotomy, and imply that there is little if any clinical significance to skipped nodules. However, because these favorable outcomes from VATS were obtained predominantly in populations with a limited disease extent, many surgeons restrict VATS to patients with a single or very few pulmonary metastases. Available studies are inherently biased because patients with single metastases are more often offered VATS.",
"   </p>",
"   <p>",
"    Specific data illustrating these points includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort study of 186 patients undergoing pulmonary metastasectomy (36 with VATS and 135 via thoracotomy), five-year overall survival (70 versus 59 percent) and recurrence-free survival (67 versus 51 percent) were not worse after VATS [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/40\">",
"       40",
"      </a>",
"      ]. However, the VATS group more often had single metastases (56 versus 21 percent), and unilateral disease (94 versus 67 percent).",
"     </li>",
"     <li>",
"      Another study attempted to minimize patient selection bias by comparing outcomes from both procedures in a relatively homogeneous population of patients with two or fewer sarcoma metastases per lung field [",
"      <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/41\">",
"       41",
"      </a>",
"      ]. When the 31 patients treated with VATS were compared to 29 patients undergoing open thoracotomy, overall survival and ipsilateral recurrence rates were similar in both groups. In this study, again, VATS patients more often had single lesions (58 versus 38 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for systematic lymph node sampling during pulmonary metastasectomy is controversial. In general, there are few (if any) long-term survivors among those with N2 disease (",
"    <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"     figure 2",
"    </a>",
"    ) leading many to conclude that documentation of mediastinal nodal involvement represents a contraindication to potentially curative pulmonary metastasectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/18,20,21,24,26\">",
"     18,20,21,24,26",
"    </a>",
"    ]. Some centers routinely evaluate the mediastinal lymph nodes only in patients with suspicious findings on CT, while others advocate routine systematic preoperative staging of the mediastinum in all patients. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Prognostic determinants'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Intraoperative staging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sampling of the nodes prior to lung resection allows for more accurate staging, and prediction of prognosis. Furthermore, the documentation of N2 nodal diseases may make nonsurgical treatment alternatives (such as chemotherapy, radiation, or radiofrequency ablation) more attractive because of the lower perceived benefit of surgery in this situation. Although some have suggested that knowing the status of the regional nodes can guide adjuvant radiotherapy, or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/18\">",
"     18",
"    </a>",
"    ], the presence of nodal metastases does not change medical management for the vast majority of tumor types metastasizing to the lung (sarcoma, colorectal cancer, breast cancer, germ cell tumor). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, successful removal of involved nodes can produce a complete resection with negative margins, which may contribute to the success of the surgery. Leaving an involved node is equivalent to having a positive margin. Removal of perihilar nodes, can frequently be accomplished by thoracoscopic enucleation while removal of enlarged nodes between the vessels and segmental bronchi often requires segmentectomy or lobectomy.",
"   </p>",
"   <p>",
"    Removal of involved nodes can prevent symptoms and complications, thereby improving quality of life. As an example, enlarged right-sided tracheobronchial nodes can compress the superior vena cava causing upper extremity and facial swelling, or erode into the main bronchus causing airway obstruction or hemoptysis.",
"   </p>",
"   <p>",
"    There are no randomized trials in which patients either did or did not undergo mediastinal node dissection prior to pulmonary metastasectomy. However, at least some data suggest that long-term survival is possible for some patients, particularly those with renal cell cancer with nodal disease that is limited to the hilar and intrapulmonary (N1) nodes (",
"    <a class=\"graphic graphic_figure graphicRef73945 \" href=\"UTD.htm?19/28/19914\">",
"     figure 2",
"    </a>",
"    ), and amenable to anatomic resection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Lymph node spread'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Repeat metastasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both epithelial cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/14\">",
"     14",
"    </a>",
"    ] and sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/57\">",
"     57",
"    </a>",
"    ], the most frequent site of relapse following pulmonary resection is in the lung. In general, sequential resections can be carried out safely to treat isolated recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of repeat metastasectomy has been evaluated retrospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4,58,59\">",
"     4,58,59",
"    </a>",
"    ]. The largest series, the International Registry of Lung Metastases, found that 53 percent of the 5206 patients undergoing resection of pulmonary metastases relapsed in the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"     4",
"    </a>",
"    ]. Among the 1042 patients who underwent repeat metastasectomy, the 5- and 10-year survival rates were 44 and 29 percent, respectively. In contrast, the median survival among patients who were not resected following relapse in one series was eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These reports suggest that repeat surgery can reestablish control in the chest in carefully selected patients. The likelihood of permanent disease control decreases with multiple sequential resections (",
"    <a class=\"graphic graphic_figure graphicRef53931 \" href=\"UTD.htm?26/51/27453\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/9\">",
"     9",
"    </a>",
"    ]. In a series of 54 patients from one institution who underwent multiple resections for pulmonary metastases, the percentage of patients achieving durable local control of disease after the second, third, fourth, and fifth procedures was 27, 19, 8, and 0 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/9\">",
"     9",
"    </a>",
"    ]. When local control in the chest is lost, survival becomes dismal with an average life expectancy of a few months (",
"    <a class=\"graphic graphic_figure graphicRef61502 \" href=\"UTD.htm?18/30/18926\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ability to treat pulmonary metastatic disease with repeated resections provides additional support for the concept that surgery can be restricted to radiographically visible lesions without an open search using manual palpation. Patients managed this way require close follow-up, with resection of lesions subsequently detected by imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/32/13834/abstract/9,59\">",
"     9,59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Timing of surgery'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive surgical resection of lung metastases in appropriately selected patients offers a chance for extended disease-free survival that would not be possible with systemic therapy. Retrospective experience has shown that the overall actuarial five- and ten-year survival rates after complete metastasectomy are about 36 and 26 percent, respectively. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Benefits of resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For appropriately selected patients, we recommend surgical resection of lung metastases rather than palliative systemic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Criteria for resection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although there are no published guidelines as to appropriate patient selection, general selection criteria should include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Control of the primary tumor, and patients should not have uncontrollable extrapulmonary disease.",
"     </li>",
"     <li>",
"      All evidence of lung metastases, including bilateral disease, should be potentially resectable.",
"     </li>",
"     <li>",
"      Adequate cardiopulmonary reserve.",
"     </li>",
"     <li>",
"      Prior to resection, an FDG-PET scan is indicated to identify any extrathoracic foci of disease. Even if there is no FDG uptake in the pulmonary nodules, we favor surgical resection for both diagnostic and therapeutic purposes. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'PET scans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain imaging prior to attempted resection of apparently isolated pulmonary metastases should be performed for patients who have tumors that frequently metastasize to the brain (eg, breast cancer, melanoma). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Brain imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to resection, thoracic evaluation with thin-section, high-resolution helical CT is preferred over conventional CT in order to maximize detection of all sites of intrathoracic disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection of one or more lung lesions may also be indicated in a patient with a known malignancy when a new primary lung cancer cannot be excluded, or to control symptomatic metastases, or to obtain tissue for a novel therapeutic strategy, preferably within the confines of a clinical trial. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not meet the criteria for pulmonary metastasectomy, stereotactic radiotherapy, radiofrequency ablation, or cryotherapy may offer an alternative to resection for local control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link\">",
"       \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"       \"Radiofrequency ablation of lung tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior to planned resection, we suggest evaluation of the mediastinal lymph nodes as would be done for a patient with a primary lung cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can be done either with mediastinoscopy prior to surgery or at thoracotomy. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Lymphadenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using video-assisted thoracoscopic surgery (VATS) rather than an open thoracotomy for patients with one or a limited number of small metastases in the peripheral one-third of one lung (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'VATS procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Open thoracotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients planned for open thoracotomy, we suggest delaying surgery for six to eight weeks to assess lesion stability. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Assessment of lesion stability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of postoperative adjuvant chemotherapy for specific histologic tumor types is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following initial complete resection, we suggest regular radiographic surveillance with chest CT scans every four months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Radiographic evidence of recurrence mandates a full evaluation of disease extent and cardiorespiratory reserve. If the indications for pulmonary metastasectomy are still met, a repeat surgical procedure is offered as an alternative to systemic therapy or other locally ablative options. A chest CT scan should be repeated six weeks after the initial observation of suspected recurrence and prior to repeat surgery, as this may reveal additional deposits of recurrence that may preclude surgery. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Repeat metastasectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Criteria for resection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/1\">",
"      Farrell J. Pulmonary metastases: pathological, clinical roentgenological study based on 78 cases at necropsy. Radiology 1935; 24:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/2\">",
"      Barney JD. Adenocarcinoma of the kidney with metastases to the lung cured by nephrectomy and lobectomy. J Urol 1939; 42:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/3\">",
"      Srinivas S, Varadhachary G. Spontaneous pneumothorax in malignancy: a case report and review of the literature. Ann Oncol 2000; 11:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/4\">",
"      Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997; 113:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/5\">",
"      Hornbech K, Ravn J, Steinbr&uuml;chel DA. Outcome after pulmonary metastasectomy: analysis of 5 years consecutive surgical resections 2002-2006. J Thorac Oncol 2011; 6:1733.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/7\">",
"      EHRENHAFT JL, LAWRENCE MS, SENSENIG DM. Pulmonary resections for metastatic lesions. AMA Arch Surg 1958; 77:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/8\">",
"      Martini N, McCormack PM. Evolution of the surgical management of pulmonary metastases. Chest Surg Clin N Am 1998; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/9\">",
"      Jaklitsch MT, Mery CM, Lukanich JM, et al. Sequential thoracic metastasectomy prolongs survival by re-establishing local control within the chest. J Thorac Cardiovasc Surg 2001; 121:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/10\">",
"      Kondo H, Okumura T, Ohde Y, Nakagawa K. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes. Int J Clin Oncol 2005; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/11\">",
"      Quiros RM, Scott WJ. Surgical treatment of metastatic disease to the lung. Semin Oncol 2008; 35:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/12\">",
"      Todd TR. The surgical treatment of pulmonary metastases. Chest 1997; 112:287S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/13\">",
"      Murthy SC, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 2005; 79:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/14\">",
"      Monteiro A, Arce N, Bernardo J, et al. Surgical resection of lung metastases from epithelial tumors. Ann Thorac Surg 2004; 77:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/15\">",
"      Reshetov AV, Iablonski PK, Orlova RV, et al. [The possibility and prognostic value of secondary lymphatic cancer spread in intrapulmonic metastases of solid tumors]. Vestn Khir Im I I Grek 2008; 167:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/16\">",
"      THOMFORD NR, WOOLNER LB, CLAGETT OT. THE SURGICAL TREATMENT OF METASTATIC TUMORS IN THE LUNGS. J Thorac Cardiovasc Surg 1965; 49:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/17\">",
"      Ercan S, Nichols FC 3rd, Trastek VF, et al. Prognostic significance of lymph node metastasis found during pulmonary metastasectomy for extrapulmonary carcinoma. Ann Thorac Surg 2004; 77:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/18\">",
"      Loehe F, Kobinger S, Hatz RA, et al. Value of systematic mediastinal lymph node dissection during pulmonary metastasectomy. Ann Thorac Surg 2001; 72:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/19\">",
"      Menon A, Milton R, Thorpe JA, Papagiannopoulos K. The value of video-assisted mediastinoscopy in pulmonary metastasectomy. Eur J Cardiothorac Surg 2007; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/20\">",
"      Welter S, Jacobs J, Krbek T, et al. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg 2007; 31:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/21\">",
"      Veronesi G, Petrella F, Leo F, et al. Prognostic role of lymph node involvement in lung metastasectomy. J Thorac Cardiovasc Surg 2007; 133:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/22\">",
"      Hamaji M, Cassivi SD, Shen KR, et al. Is lymph node dissection required in pulmonary metastasectomy for colorectal adenocarcinoma? Ann Thorac Surg 2012; 94:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/23\">",
"      Inoue M, Kotake Y, Nakagawa K, et al. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000; 70:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/24\">",
"      Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/25\">",
"      Pfannschmidt J, Klode J, Muley T, et al. Nodal involvement at the time of pulmonary metastasectomy: experiences in 245 patients. Ann Thorac Surg 2006; 81:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/26\">",
"      Khan JH, McElhinney DB, Rahman SB, et al. Pulmonary metastases of endocrine origin: the role of surgery. Chest 1998; 114:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/27\">",
"      Collie DA, Wright AR, Williams JR, et al. Comparison of spiral-acquisition computed tomography and conventional computed tomography in the assessment of pulmonary metastatic disease. Br J Radiol 1994; 67:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/28\">",
"      Remy-Jardin M, Remy J, Giraud F, Marquette CH. Pulmonary nodules: detection with thick-section spiral CT versus conventional CT. Radiology 1993; 187:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/29\">",
"      Parsons AM, Ennis EK, Yankaskas BC, et al. Helical computed tomography inaccuracy in the detection of pulmonary metastases: can it be improved? Ann Thorac Surg 2007; 84:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/30\">",
"      Mery CM, Pappas AN, Bueno R, et al. Relationship between a history of antecedent cancer and the probability of malignancy for a solitary pulmonary nodule. Chest 2004; 125:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/31\">",
"      Internullo E, Cassivi SD, Van Raemdonck D, et al. Pulmonary metastasectomy: a survey of current practice amongst members of the European Society of Thoracic Surgeons. J Thorac Oncol 2008; 3:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/32\">",
"      Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/33\">",
"      Reinhardt MJ, Wiethoelter N, Matthies A, et al. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging 2006; 33:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/34\">",
"      Iagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006; 27:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/35\">",
"      Pastorino U, Veronesi G, Landoni C, et al. Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. J Thorac Cardiovasc Surg 2003; 126:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/36\">",
"      Rusch VW. Pulmonary metastasectomy. Current indications. Chest 1995; 107:322S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/37\">",
"      Migliore M, Deodato G. Thoracoscopic surgery, video-thoracoscopic surgery, or VATS: a confusion in definition. Ann Thorac Surg 2000; 69:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/38\">",
"      Chojniak R, Younes RN. Pulmonary metastases tumor doubling time: assessment by computed tomography. Am J Clin Oncol 2003; 26:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/39\">",
"      Tanaka Y, Maniwa Y, Nishio W, et al. The optimal timing to resect pulmonary metastasis. Eur J Cardiothorac Surg 2008; 33:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/40\">",
"      Carballo M, Maish MS, Jaroszewski DE, Holmes CE. Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study. J Cardiothorac Surg 2009; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/41\">",
"      Nakajima J, Takamoto S, Tanaka M, et al. Thoracoscopic surgery and conventional open thoracotomy in metastatic lung cancer. Surg Endosc 2001; 15:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/42\">",
"      Nakajima T, Yasufuku K, Iyoda A, et al. The evaluation of lymph node metastasis by endobronchial ultrasound-guided transbronchial needle aspiration: crucial for selection of surgical candidates with metastatic lung tumors. J Thorac Cardiovasc Surg 2007; 134:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/43\">",
"      Margaritora S, Porziella V, D'Andrilli A, et al. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach? Eur J Cardiothorac Surg 2002; 21:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/44\">",
"      Parsons AM, Detterbeck FC, Parker LA. Accuracy of helical CT in the detection of pulmonary metastases: is intraoperative palpation still necessary? Ann Thorac Surg 2004; 78:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/45\">",
"      Cerfolio RJ, McCarty T, Bryant AS. Non-imaged pulmonary nodules discovered during thoracotomy for metastasectomy by lung palpation. Eur J Cardiothorac Surg 2009; 35:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/46\">",
"      Mineo TC, Ambrogi V, Mineo D, Pompeo E. Transxiphoid hand-assisted videothoracoscopic surgery. Ann Thorac Surg 2007; 83:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/47\">",
"      Roth JA, Pass HI, Wesley MN, et al. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas. Ann Thorac Surg 1986; 42:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/48\">",
"      Putnam JB Jr, Suell DM, Natarajan G, Roth JA. Extended resection of pulmonary metastases: is the risk justified? Ann Thorac Surg 1993; 55:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/49\">",
"      Dowling RD, Keenan RJ, Ferson PF, Landreneau RJ. Video-assisted thoracoscopic resection of pulmonary metastases. Ann Thorac Surg 1993; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/50\">",
"      Saisho S, Nakata M, Sawada S, et al. Evaluation of video-assisted thoracoscopic surgery for pulmonary metastases: 11-years of experience. Surg Endosc 2009; 23:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/51\">",
"      Goya T, Miyazawa N, Kondo H, et al. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989; 64:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/52\">",
"      Gossot D, Radu C, Girard P, et al. Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach? Ann Thorac Surg 2009; 87:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/53\">",
"      De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. Chest 1999; 115:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/54\">",
"      Mutsaerts EL, Zoetmulder FA, Meijer S, et al. Long term survival of thoracoscopic metastasectomy vs metastasectomy by thoracotomy in patients with a solitary pulmonary lesion. Eur J Surg Oncol 2002; 28:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/55\">",
"      Mutsaerts EL, Zoetmulder FA, Meijer S, et al. Outcome of thoracoscopic pulmonary metastasectomy evaluated by confirmatory thoracotomy. Ann Thorac Surg 2001; 72:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/56\">",
"      Ludwig C, Cerinza J, Passlick B, Stoelben E. Comparison of the number of pre-, intra- and postoperative lung metastases. Eur J Cardiothorac Surg 2008; 33:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/57\">",
"      Temple LK, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg 2002; 14:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/58\">",
"      Robert JH, Ambrogi V, Mermillod B, et al. Factors influencing long-term survival after lung metastasectomy. Ann Thorac Surg 1997; 63:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/32/13834/abstract/59\">",
"      Kandioler D, Kr&ouml;mer E, T&uuml;chler H, et al. Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998; 65:909.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7815 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-F2EAE850DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13834=[""].join("\n");
var outline_f13_32_13834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BENEFITS OF RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Criteria for resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognostic determinants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Completeness of resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Disease-free interval",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Number of lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lymph node spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Assessment of lesion stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PET scans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Brain imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Need for preoperative tissue diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Choice of technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Intraoperative staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Open thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Unilateral radiographic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Bilateral radiographic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Role for extended resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      VATS procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Repeat metastasectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/7815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7815|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/41/20126\" title=\"figure 1\">",
"      Probability of incomplete pulmonary nodule resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/28/19914\" title=\"figure 2\">",
"      IASLC lymph node map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/51/27453\" title=\"figure 3\">",
"      Survival benefit with pulmonary metastasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/30/18926\" title=\"figure 4\">",
"      Local control and survival pulmonary metastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/53/34651\" title=\"table 1\">",
"      Pulm mets surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9946?source=related_link\">",
"      Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17080?source=related_link\">",
"      Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20900?source=related_link\">",
"      Cryoablation of lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=related_link\">",
"      Radiofrequency ablation of lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17143?source=related_link\">",
"      Stereotactic body radiation therapy for primary and metastatic lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_32_13835="Cytogenetic abnormalities AMM";
var content_f13_32_13835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cytogenic abnormalties in agnogenic myeloid metaplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20q-",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13q-",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        abn chromosome 1",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +8",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +9",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -7",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        abn chromosome 12",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Includes patients with post-polycythemia and post-thrombocythemia myeloid metaplasia.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tefferi, A, et al. Br J Haematol 2001; 113:763.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13835=[""].join("\n");
var outline_f13_32_13835=null;
var title_f13_32_13836="WHO neuroendo tum lung 2004";
var content_f13_32_13836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2004 WHO criteria for the diagnosis of pulmonary neuroendocrine tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typical carcinoid",
"       </td>",
"       <td>",
"        Carcinoid morphology and &lt;2 mitoses/2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPFs), lacking necrosis and &gt;0.5 cm",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Atypical carcinoid",
"       </td>",
"       <td>",
"        Carcinoid morphology with 2-10 mitoses/2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPFs) or necrosis (often punctuate)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Large cell neuroendocrine carcinoma",
"       </td>",
"       <td>",
"        Neuroendocrine morphology (organoid nesting palisading rosettes, trabeculae):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High mitotic rate &gt;10/2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPFs), median of 70/2 mm",
"        <sup>",
"         2",
"        </sup>",
"        ;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrosis (often large zones);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytologic features of a NSCLC: large cell size, low nuclear to cytoplasmic ratio, vesicular or fine chromatin, and/or frequent nucleoli; some tumors have fine nuclear chromatin and lack nucleoli but qualify as NSCLC because of large cell size and abundant cytoplasm; and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive immunohistochemical staining for one or more NE markers (other than neuron-specific enolase) and/or NE granules by electron microscopy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Small cell neuroendocrine carcinoma",
"       </td>",
"       <td>",
"        Small size (generally less than the diameter of three resting lymphocytes);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scant cytoplasm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuclei: finely granular nuclear chromatin, absent or faint nucleoli;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High mitotic rate: &gt;11 mitoses/2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPFs), median of 80/2 mm",
"        <sup>",
"         2",
"        </sup>",
"        (10 HPFs); and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent necrosis, often in large zones",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HPF: high-power field; NSCLC: non-small cell lung carcinoma; NE: neuroendocrine.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13836=[""].join("\n");
var outline_f13_32_13836=null;
var title_f13_32_13837="DDx neonatal cholestasis";
var content_f13_32_13837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of neonatal cholestasis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extrahepatic obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrahepatic biliary atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choledochal cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inspissated bile/mucous plug",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholelithiasis or biliary sludge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors/masses (intrinsic and extrinsic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal sclerosing cholengitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous perforation of the bile ducts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV, cytomegalovirus, herpes, rubella, parvovirus B19, echovirus, adenovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary tract infection, sepsis, syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Protozoal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic/genetic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alagille syndrome (syndromic paucity of the interlobular bile ducts or arteriohepatic dysplasia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsyndromic paucity of the interlobular bile ducts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Progressive familial intrahepatic cholestasis, types 1-3 (Byler disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital hepatic fibrosis/Caroli's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Disorders of carbohydrate metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Galactosemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fructosemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type IV gylcogenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Disorders of amino acid metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tyrosinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Disorders of lipid metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wolman, Niemann-Pick, Gaucher",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Disorders of bile acid synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-beta-hydroxysteroid dehydrogenase/isomerase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-oxosteroid 5-beta reductase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other metabolic defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citrin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-1-antitrypsin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypopituitarism (septo-optic dysplasia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Toxic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alloimmune&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational alloimmune liver disease (Neonatal hemochromatosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Idiopathic\" neonatal hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock/hypoperfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal obstruction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13837=[""].join("\n");
var outline_f13_32_13837=null;
var title_f13_32_13838="C1 burst fracture";
var content_f13_32_13838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Burst (Jefferson) fracture of C1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Jefferson fracture of C1 is highly unstable and occurs when a vertical compression force is transmitted through the occipital condyles to the lateral masses of the atlas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13838=[""].join("\n");
var outline_f13_32_13838=null;
var title_f13_32_13839="Asthma severity 12 and up";
var content_f13_32_13839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71425%7EPULM%2F51579%7EPULM%2F61691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71425%7EPULM%2F51579%7EPULM%2F61691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in youths greater than or equal to 12 years of age and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (youths &ge;12 years of age and adults)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <p>",
"         Impairment",
"        </p>",
"        <p>",
"         Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC:",
"        </p>",
"        <p>",
"         8-19 yr 85 percent",
"        </p>",
"        <p>",
"         20-39 yr 80 percent",
"        </p>",
"        <p>",
"         40-59 yr 75 percent",
"        </p>",
"        <p>",
"         60-80 yr 70 percent",
"        </p>",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not &gt;1x/day",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC normal",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &ge;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC normal",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;60 but &lt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC reduced 5 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC reduced &gt;5 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity for patients who are not currently taking long-term control medications.",
"    </strong>",
"    Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;85 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = 60-80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC = 75-80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 in 1 year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity in children who are not currently taking long-term control medication.",
"    </strong>",
"    Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (children 0-4 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1-2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 exacerbations in 6 months requiring oral steroids, or &ge;4 wheezing episodes/1 year lasting &gt;1 day AND risk factors for persistent asthma",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Exacerbations of any severity may occur in patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity in children who are not currently taking long-term control medication.",
"    </strong>",
"    Level of severity is determined by both impairment and risk. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral corticosteroids in the past 6 months, or &ge;4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_32_13839=[""].join("\n");
var outline_f13_32_13839=null;
 